US3829573A - Hexahydro pyrazinoquinolines as antischistosomal agents - Google Patents

Hexahydro pyrazinoquinolines as antischistosomal agents Download PDF

Info

Publication number
US3829573A
US3829573A US00379009A US37900973A US3829573A US 3829573 A US3829573 A US 3829573A US 00379009 A US00379009 A US 00379009A US 37900973 A US37900973 A US 37900973A US 3829573 A US3829573 A US 3829573A
Authority
US
United States
Prior art keywords
hexahydro
quinoline
pyrazino
methyl
carbon atoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US00379009A
Inventor
H Richards
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Priority to US00379009A priority Critical patent/US3829573A/en
Application granted granted Critical
Publication of US3829573A publication Critical patent/US3829573A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18Halogen atoms or nitro radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Definitions

  • Typical members include 7,-chloro-8-methyl-2,3,4,4a,5,6- hexahydrol H-pyra2ino-[ l,2-a]-quinoline and 8- hydroxymethyl-9-chloro-2,3,4,4a,5,6-hexahydro-l H- pyraZino-[ l ,2-a1-quinoline.
  • This invention relates to certain new and useful hexahydro pyrazinoquinoline compounds of principal interest to those in the field of chemotherapy. More particularly, it is concerned with various novel substituted hexahydro pyrazinoquinolines and their non-toxic acid addition salts, which are of especial value in view of their anti-schistosomal properties.
  • R is a member selected from the group consisting of methyl, hydroxymethyl and formyl;
  • R is a member selected from the group consisting of nitro, cyano, fluorine, chlorine and bromine located at either the 7- or 9- position of the molecule; and
  • R and R are each a member selected from the group consisting of hydrogen and alkyl having from one to six carbon atoms; and the N-oxide derivatives of said base compounds wherein R is
  • novel substituted hexahydro pyrazinoquinoline compounds are extremely useful when employed in the field of drug therapy as anti-schistosomal agents.
  • novel compounds of this invention are all selected from the group consisting of substituted 2,3,4,4a,5,6-hexahydrol H-pyrazino- [l,2-a]-quinoline bases of the formula:
  • R is a member selected from the group consisting of hydrogen, allyl, alkyl having from one to five carbon atoms, hydroxyalkyl having from twoto six carbon atoms, cyanoalkyl having up to six carbon atoms in the alkyl moiety, alkanoyloxyalkyl having from two to six carbon atoms in the oxyalkyl moiety and up to six carbon atoms in the alkanoyl moiety, cycloalkyl having up to six carbon atoms, phenylalkyl having up to three carbon atoms in the alkyl moiety, carboxyalkyl having up to six carbon atoms in the alkyl moiety, alkanoyl and carboxyalkanoyl each having up the aforesaid structural formula is either hydrogen or an alkyl group containing from one to four carbon atoms, R is methyl or hydroxymethyl, R is nitro or chlorine located at either the 7-
  • Typical member compounds of the preferred class include such 7- or 9-nitro or chloro substituted 8-methyl- 2,3,4,4a,5,6-hexahydrol H-pyrazino-[ 1 ,2-a]- quinolines as 8-methyl-9-nitro-2,3,4,4a,5,6-hexahydrolH-pyrazino-[ l,2-a]-quinoline, 3-n-propyl-8-methyl-9- nitro-2,3 ,4,4a,5 ,6-hexahydro-1H-pyrazino-[ l ,2-a]- quinoline, 3-isopropyl-8-methyl-9-nitro-2,3,4,4a,5,6- hexahydro- 1 H-pyrazino-[ l ,2-a]-quinoline, 7-chloro-8- methyl-2,3 ,4,4a,5,6-hexahydrol H-pyrazino-[ l,2-a]- quinoline, 8-methyl-9-chlor
  • the aforementioned 2-aminornethyl-6-methyll ,2,3 ,4- tetrahydroquinoline starting material may beprepared by catalytic reduction of the corresponding 6-methylquinoline-2-aldehyde in the presence of ammonia to give the intermediate 2-aminomethyl-6- methylquinoline, which is then further reduced by catalytic hydrogenation'to afford the desired compound.
  • novel hexahydro pyrazinoquinoline compounds of the same type as indicated above may also be prepared from the aforementioned 2aminomethyl-6-methylquinoline type compounds using bromoacetyl chloride as the cyclizing agent to yield the corresponding 8-methyl-2-oxo-2,3,4-trihydro-lH-pyrazino- [l,2-a]-quinolinium bromide as intermediate, followed by catalytic reduction of the hetero-aromatic ring and lithium aluminum hydride reduction of the keto group to give the corresponding 8-methyl-2,3,4,4a,5,6- hexahydro-l H-pyrazino-[ l ,2-a]-quinoline, which can be nitrated as before.
  • novel compounds of the present invention in which R is other than hydrogen are simply prepared from those already obtained as aforesaid (where R is hydrogen) by using synthetic methods well-known to those skilled in the art for substitution on the free hydrogen atom of secondary amines.
  • substituted hexahydropyrazinoquinoline compounds of the invention in which R, is alkyl, hydroxyalkyl, aralkyl or cycloalkyl may be prepared by simply introducing such a group into the Z-aminomethyl or 2-(B-hydroxyethylamino)- methylquinolines or tetrahydroquinoline starting materials, hereinbefore described and utilized for preparing those novel compounds where R is hydrogen.
  • the substitution step would necessarily be carried out before the cyclization reaction and subsequent nitration in these particular instances.
  • Suitable N- substituted Z-aminomethyl and/or Z-(B-hydroxyethylamino)methyl quinolines and tetrahydroquinolines required as starting materials in this alternate series of reactions may, in turn, be readily prepared starting from the appropriate -methylquinoline-Z-carboxylic acid, 2-halomethyl-6-methylquinoline or -methylquinoline-2-aldehyde, as the case may be, using methods that have previously been described and are illustrated in Examples XXVI-XXX hereinafter.
  • novel hexahydro pyrazinoquinoline compounds of the invention in which R, is cyano or halogen rather than nitro, as previously described can simply be prepared from the latter (i.e., where R is nitro) by reduction to the amine, followed by diazotisation and subsequent conversion to the 7- or 9-halo or cyano compounds, as the case may be, using wellknown methods of organic chemistry.
  • compounds of the invention in which R is hydroxymethyl or formyl can be prepared from those where R is methyl by using an appropriate microorganism like Aspergillus sclerotiorum Huber, publicly available from the Centralbureau voor Schimmelcultures at Baarn, Netherlands, whereby the methyl group is converted by oxidation to one of the other two groups during the course of the over-all fermentation, as illustrated by Example XXXI hereinafter.
  • an appropriate microorganism like Aspergillus sclerotiorum Huber, publicly available from the Centralbureau voor Schimmelcultures at Baarn, Netherlands, whereby the methyl group is converted by oxidation to one of the other two groups during the course of the over-all fermentation, as illustrated by Example XXXI hereinafter.
  • N- oxide derivatives of the compounds of this invention i.e., N-oxide derivatives of the aforementioned novel substituted hexahydro pyrazinoquinolines in which R, is other than hydrogen
  • R is other than hydrogen
  • N-oxide derivatives of the aforementioned novel substituted hexahydro pyrazinoquinolines in which R, is other than hydrogen may be prepared by simply using well-known synthetic methods to effect such a conversion from the parent compound, e.g., oxidation via 30 percent hydrogen peroxide or benzoyl peroxide, etc.
  • substituted hexahydro pyrazinoquinoline compounds of this invention all possess an asymmetric carbon atom at position 4A of the molecule, they may exist in separated dand l-optically active forms, as well as in racemic dl-mixtures necessarily produced by the present synthetic methods as hereinbefore described.
  • the invention contemplates the d-, land racemic forms within its scope.
  • the acids which are used to prepare the pharmaceutical]y-acceptable acid addition salts of this invention are those which form non-toxic acid addition salts containing pharmacologically acceptable anions, such as the hydrochloride and sulfate, when reacted with the aforementioned hexahydro pyrazinoquinoline base compounds.
  • Preferred acids for use in this connection include hydrochloric acid, hydrobromic acid, hydroiodic acid, nitric acid, sulfuric acid.
  • phosphoric acid acetic acid, lactic acid, citric acid, tartaric acid, oxalic acid, gluconic acid, saccharic acid, benzoic acid, succinic acid, maleic acid, methanesulfonic acid, ethanesulfonic acid, benzene-sulfonic acid, p-toluenesulfonic acid, picric acid, amsonic acid, (4,4- diaminostilbene-2,2-disulfonic acid) and pamoic acid l ,l-methylene-bis-Z-hydroxy-3-naphthoic acid).
  • the hexahydro pyrazinoquinoline compounds of this invention are therapeutically valuable as anti-schistosomal agents, particularly in view of their ability to move adult schistosome organisums from their normal sites in the mesenteric veins on to the liver. Hence, they are useful in the treatment of schistosomiasis and/or for the control of schistosome infections with the preferred compounds of this invention being especially useful in this connection in view of the highly potent nature of their anti-schistosomal action and lack of significant side effects.
  • 3-isopropyl-8-8-methyl-9-nitro- 2,3 ,4,4a,5 ,6-hexahydrol Hpyrazino-[ l ,2-a]-quinoline maleate a typical and preferred agent of the present invention
  • these herein described compounds can be administered as anti-schistosomal agents by either the oral or parenteral routes of administration. In general, they are ordinarily administered in dosages ranging from about 5.0 mg. to about 150 mg. per kg. of body weight per day, although variations will necessarily occur depending upon the weight and condition of the subject being treated and the particular route of administration chosen.
  • novel compounds of this invention can be administered in wide variety of different dosage forms, i.e., they may be combined with various pharmaceutically acceptable inert carriers in the form of tablets, capsules, lozenges, troches, hard candies, powders, sprays, aqueous sus pensions, injectable solutions, elixirs, syrups, and the like.
  • Such carriers include solid diluents or fillers, sterile aqueous media and various non-toxic organic solvents, etc.
  • oral pharmaceutical formulations can be suitably sweetened and/or flavored by means of various agents of the type commonly employed for just such purposes.
  • the therapeutically useful compounds of this invention are present in such dosage forms at concentration levels ranging from about 0.5 to about 90 percent by weight of the total composition, i.e., in amounts which are sufficient to provide the desired unit dosage previously indicated.
  • tablets containing various excipients such as sodium citrate, calcium carbonate and dicalcium phosphate may be employed along with various disintegrants such as starch and preferably potato or tapioca starch, alginic acid and certain complex silicates, together with binding agents such as polyvinylpyrrolidone, sucrose, gelatin and acacia.
  • disintegrants such as starch and preferably potato or tapioca starch, alginic acid and certain complex silicates, together with binding agents such as polyvinylpyrrolidone, sucrose, gelatin and acacia.
  • binding agents such as polyvinylpyrrolidone, sucrose, gelatin and acacia.
  • lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc are often very useful for tabletting purposes.
  • Solid compositions of a similar type may also include lactose or milk sugar as well as high molecular weight polyethylene glycols.
  • the essential active ingredient therein may be combined with various sweetening or flavoring agents, coloring matter or dyes and, if so desired, emulsifying and/or suspending agents as well, together with such diluents as water, ethanol, propylene glycol, glycerin and various like combinations thereof.
  • solutions of these particular hexahydro pyrazinoquinolines in seasame or peanut oil or in aqueous-propylene glycol or N,N-dimethylformamide may be employed, as well as sterile aqueous solutions of the corresponding watersoluble, non-toxic mineral and organic acid addition salts previously enumerated (e.g., the methane sulfonate salt).
  • aqueous solutions should be suitably buffered if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose.
  • these particular aqueous solutions are especially suitable for intravenous, intramuscular, subcutaneous and intraperitoneal injection purposes.
  • the sterile aqueous media employed are all readily obtainable by standard techniques well-known to those skilled in the art.
  • EXAMPLE I A solution consisting of 200 g. of l-benzoyl-Z-cyano- 6-methyl 1,2-dihydro-quinoline (prepared by the method of Reissert starting from -methylquinoline and using benzoyl chloride and potassium cyanide as mixture consisting of 90 percent by volume of 5N hydrochloric acid and 10 percent by volume of ethanol, and refluxed overnight for a period of approximately 18 hours. After allowing to cool to room temperature, the resulting mixture was made strongly basic with 5N sodium hydroxide, and the basic solution was thereafter extracted with diethyl ether and filtered. The insoluble material on the filter funnel was then dissolved in 2N hydrochloric acid, treated with alkali as before and extracted with diethyl ether.
  • a finely-ground powdered mixture was then prepared consisting of 8.8 g. (0.05 mole) of 2- aminomethyl-6-methyl-l ,2,3 ,4-tetrahydro-quinoline, obtained as described above, and 11.8 g. (0.10 mole) of dimethyl oxalate.
  • the latter mixture was then heated in an open vessel on the steam bath for a period of 18 hours.
  • the resulting brown mobile oil, obtained in this manner was allowed to cool before treatment with 20 ml. of acetone. On boiling the latter mixture, followed by cooling, there was finally a white solid material as precipitate.
  • the latter material was then recovered by means of filtration, washed with a little cold acetone and subsequently dried in vacuo to afford the desired product in crude form.
  • a solution consisting of 0.315 g. of concentrated nitric acid (d. 1.5) in 5 ml. of concentrated sulfuric acid was then prepared and added to a well-stirred, ice cold solution of 1.15 g. of 8-methyl-2,3,4,4a,5,6-hexahydrolH-pyrazine-[1,2-a]-quinoline in 25 ml. of concentrated sulfuric acid.
  • the resulting mixture was then stirred at 5C. for an additional period of 45 hours.
  • the crude nitrated product was poured into a mixture of ice and water, and subsequently made basic with solid potassium carbonate and filtered. Upon extraction of the combined chloroform extracts under reduced pressure, there was ultimately obtained a 1.0 g.
  • EXAMPLE Ill A mixture consisting of 5.0 g. of 8-methyl- 2,3,4,4a,5,6-hexahydro-1H-pyrazino-[ 1 ,2-a]-quino1ine in 25 ml. of acetic anhydride was refluxed for a two and one-half hour period, and the resulting dark solution was then poured into ice-water (250 ml.). After allowing the precipitated solid to stand for one hour in the aqueous medium, it was subsequently extracted with two-200 ml. portions of ethyl acetate. The combined extracts were then washed with 10 percent sodium bicarbonate solution, followed by water and dried over anhydrous magnesium sulfate.
  • Nitration of 1.98 g. of 3-ethyl-8-methyl-2,3,4,4a,5,6- hexahydro-lH-pyrazino-[1,2-a]-quinoline was then carried out with nitric-sulfuric acid as reagent in the same manner as described in the previous example for the nitration of the corresponding 3,8-dimethyl compound.
  • the product obtained was 3-ethyl-8-methyl-9-nitro-2 ,3 ,4,4a,5 ,6-hexahydro-1H- pyrazino-[1,2-a]-quinoline, which after conversion to the maleate and recrystallization from ethyl acetatemethanol (10:1by volume) gave 1.0 g.
  • Example W A solution consisting of 10 g. of 2-chloromethyl-6- methyl-quinoline and 16.2 g. of N- isopropylaminoethanol dissolved in 100 ml. of absolute ethanol was refluxed for a period of six hours. The alcohol solvent was then removed in vacuo and the residual oil basified with 2N sodium hydroxide solution, followed by subsequent extraction with chloroform. The combined chloroform extracts were dried over anhydrous magnesium sulfate, filtered and the resulting filtrate evaporated under reduced pressure to give a black viscous oil, which on subsequent distillation afforded 9.4 g. of 2-N-(B-hydroxyethyl)-N- isopropylaminomethyl-6-methylquinoline as a thick red oil, b.p. l55-l58C./0.25 mm. Hg.
  • EXAMPLE V The procedure described in Example 111 was repeated except that propionic anhydride was substituted for acetic anhydride as reagent in the first stage and there was ultimately obtained, in this manner, a 0.9 g. yield of 3-n-propyl-8-methyl-9-nitro-2,3,4,4a,5,6- hexahydro-1H-pyrazino-[ 1 ,2-a]-quinoline maleate in the form of a yellow-brown powder, m.p. 169-170C.
  • EXAMPLE V111 A solution consisting of 0.78 g. of 8-methyl-9-nitro- 2,3,4,4a,-5,6-hexahydro-1H-pyrazino-[ l,2-a]- quinoline in 20 ml. of dry benzene containing 0.29 g. of triethylamine was stirred at 0C. in an ice-water bath, while 0.3 g. of ethyl chloroformate dissolved in 5 ml. of dry benzene was slowly added thereto during the course of a 30-minute period. The resulting mixture was then stirred for an additional two hours at ambient temperatures, filtered and the residue washed dry with diethyl ether.
  • EXAMPLE X A solution consisting of 0.80 g. of 3,8'-dimethyl-9- nitro-2,3,4,42,5,6-hexahydro-1H-pyrazino-[1,2-a]- quinoline dissolved in ml. of ethanol was hydrogenated over 80 mg. of 10 percent palladium-on-charcoal catalyst at 25C. and 100 p.s.i.g. pressure of hydrogen for a period of 3.5 hours. The catalyst was then removed by means of filtration and the solvent evaporated under reduced pressure to afford 3,8-dimethyl-9- amino-2,3 ,4,4a,5 ,6-hexahydrol H-pyrazino-[ 1 ,2-a]- quinoline as a brown residual oil.
  • the latter material which was viscous in nature, was then dissolved in 1.3 ml. of concentrated hydrochloric acid and 1 g. of ice and subsequently treated a solution of 180 mg. of sodium nitrite in 1.0 ml. of water while at C.
  • the solution of the diazonium salt was then added at 0C. to a solution of freshly prepared cuprous chloride in 1.3 ml. of concentrated hydrochloric acid.
  • the cuprous chloride had previously been obtained by mixing hot aqueous solutions of cupric sulfate (0.84 g.) and sodium chloride (0.22 g.) in 3.0 ml. of water, and thereafter washing the resulting pale green precipitate by means of decantation.
  • the resulting brown aqueous suspension obtained as indicated above, was subsequentlyv stirred and allowed to warm very slowly to room temperature 25C.), at which point it was then heated to 60C. via a steam-bath and allowed to cool once again.
  • the resulting solution was then basified with 5N sodium hydroxide solution, extracted with diethyl ether and the combined ether extracts subsequently dried over anhydrous magnesium sulfate.
  • the latter material was then chromatographed on neutral alumina, using chloroform as the eluent, to afford 150 mg.
  • the above product (5.0 g.) was then diazotized and treated with cuprous chloride in the same manner as described in the previous example for the corresponding 3-methyl compound. After basification with 5N so dium hydroxide solution, the resulting product was extracted into chloroform and the chloroform extracts subsequently washed with water, dried over anhydrous magnesium sulfate and filtered. The chloroform filtrate was then concentrated in vacuo and the residual oil so obtained (essentially, crude 8-methyl-9-chloro- 2,3,4,4a,5,6-hexahydro-1H-pyrazino-[ l,2-a]- quinoline) was taken up in a small amount of ethyl acetate.
  • EXAMPLE XII A solution consisting of g. of 2,6-dimethyl-5- chloroquinoline dissolved in 600 ml. of dioxane was added rapidly to a well-stirred solution of selenium dioxide (60 g.) in a mixture of 500 ml. of dioxane and 24 ml. of water. The resulting mixture was then stirred and refluxed for a period of three hours, followed by cooling to room temperature and subsequent extraction with chloroform. The combined chloroform extracts were then dried over anhydrous magnesium sulfate and filtered, and the resulting filtrate thereafter concentrated in vacuo to afford a solid residue.
  • a solution consisting of 5 g. of the above product in 250 ml. of water was treated with Adams platinum oxide catalyst (0.2 g.) and hydrogenated at 25C. under a pressure of 30 p.s.i.g. of hydrogen for a period of 5.5 hours.
  • the solution was then filtered to remove the catalyst and the filtrate subsequently made alkaline by the addition of aqueous sodium hydroxide solution.
  • the product then separated from the solution as a gummy solid, which was thereafter extracted into chloroform.
  • the chloroform extract thus obtained was washed with water and dried over anhydrous magnesium sulfate, and the subsequently dry filtrate thereafter concentrated in vacuo to afford a solid residue. Crystallization of the latter material from petroleum ether (b.p.
  • the basified aqueous solution was next extracted with two-75 ml. portions of chloroform and the chloroform extracts were subsequently dried over anhydrous magnesium sulfate, filtered and thereafter concentrated in vacuo to yield a dark-red oil as residual liquid.
  • the latter substance was taken up in ethanol, whereby a yellow crystalline material soon deposited from said solution. After collecting the crystals by means of filtration and recrystallizing same from ethanol, there was finally obtained a 1.2 g.
  • EXAMPLE xvni A culture of Aspergillus Sclerotiorum Huber is grown in several 300 ml. Erlenmeyer flasks each containing 50 ml. aliquots of the hereinafter more fully described soybean-glucose nutrient medium, which had previously been sterilized via an autoclave at 15 p.s.i.g. pressure for a period of 35 minutes. After shaking at 28C. for a period of 24 hours, via a shaker apparatus rotating at approximately 230 rpm, the resulting incolum is added (at a level of 7.5 percent by volume) under sterile conditions and with constant agitation to a fermenter pot containing two liters of said same nutrient medium having the following composition:
  • the inoculated medium in the fermenter is then agitated at 1380 rpm. and simultaneously aerated with one liter of air per minute at a temperature of 28C. for a period of 47 hours.
  • the pH of the resulting medium is readjusted, if necessary, to pH 6.5 with added sulfuric acid.
  • 0.75 g. of 3 -n-propyl-8-methyl-9-nitro-2,3 ,4,4a,5 ,6- hexahydro-l H-pyrazino-[ 1,2-a]-quinoline maleate, dissolved in ml. of distilled water, is added to the mixture, and agitation and aeration are both thereafter continued for a period of 23 hours.
  • the pH is adjusted to pH 8.0 with sodium hydroxide and the mixture is then extracted exhaustively with several portions of methylene chloride.
  • the combined organic extracts are next dried over anhydrous sodium sulfate and filtered, and the filtrate subsequently concentrated in vacuo to near dryness at a temperature below 40C.
  • the solid residue obtained in this manner is then extracted with methanol (total volume, 50 ml.) at room temperature, and the decanted extracts are subsequently filtered and treated with sodium borohydride, added in small portions over a period of 30 minutes with stirring, to reduce 8-formyl compound present in the mixture to the corresponding S-hydroxymethyl compound.
  • the so-treated methanol solution is then allowed to stand overnight 16 hours) at room temperature and diluted with five volumes of diethyl ether. After washing the resulting ethereal solution with water and drying over anhydrous magnesium sulfate, the ethereal filtrate is subjected to vacuum distillation in a water-bath at 40C.
  • the other 8-hydroxymethyl compounds of the invention are similarly prepared using the appropriate 8-methyl-2,3 ,4,4a,5 ,6-hexahydro- 1 H- pyrazino-[ l,2-a]-quinoline salt as substrate in each case.
  • N-oxide compounds of this invention where R is other than hydrogen, are each similarly formed by merely employing the appropriate 3-substituted 2,3,4,4a,5 ,6-hexahydrol I-I-pyrazino- [l,2-a]quinoline base as starting material in the above reaction procedure in place of the particular base compound used previously.
  • EXAMPLE XXIV The nitrate, sulfate, phosphate, acid phosphate, acetate, lactate, citrate acid citrate, tartrate, bitartrate, succinate, maleate, gluconate, saccharate, gluconate, methanesulfonate, ethanesulfonate, benzenesulfonate 21 and p-toluenesulfonate salts of each of the substituted hexahydro pyrazinoquinoline bases previously described in Examples XX-XXI of the instant specification are all each individually prepared by separately dissolving in a suitable amount of ethanol the proper molar amounts of the respective acid and the appropriate organic base compound and the mixing the two solutions together, followed by the addition of diethyl ether to the resulting reaction solution in order to effect precipitation of the desired acid addition salt therefrom.
  • the organic layer is separated and extracted 3 times with 1 liter of 2N hydrochloric acid.
  • the combined acid layers are washed with methylene dichloride (500 ml.) and then basified with sodium carbonate, when 2-chloromethyl-6- methylquinoline separated as a pale buff solid. Filtramethylene dichloride.
  • the combined organic layers are dried and evaporated to yield 2-isopropylamino-5- methylquinoline as a dark oil (249 g.).
  • EXAMPLE XXlX l A solution of 10 g. of 2-bromomethyl-7-chloro-6- methylquinoline in a mixture of 100 ml. of ethanol and 200 ml. chloroform at room temperature is added over a period of 5 minutes to a solution of 8.1 g. of diethylamine in 100 ml. ethanol with stirring. The solution is then allowed to stand at room temperature for 15 hours and the solvents are distilled off under vacuum. The oily residue is triturated with about 100 ml. water, the product extracted into chloroform and traces of excess diethylamine removed by washing the chloroform solution with water three times.
  • the chloroform solution is then dried over magnesium sulfate and distilled in vacuo to dryness.
  • the residual oil is dissolved in about 200 ml. of dry ether and dry hydrogen chloride gas is bubbled through the solution to precipitate 7-chloro-2- dimethylaminomethyl-6-methylquinoline hydrochloride.
  • the salt crystallized on standing and is collected and recrystallized from ethanol, with a little ether added to ensure a good recovery of product. This gave 6.6 g. of white crystalline material of m.p. 196202C.
  • the fermenters are inoculated with 7.5 percent by volume of a twenty-four hour old culture of Aspergillus sclerotiorum Huber grown at 28C. in 50 ml. aliquots of the above described soybean-glucose medium contained in 200 ml. Erlenmeyer flasks, placed on a shaker rotating at approximately 230 r.p.m.
  • the inoculated fermenters are agitated at 1380 r.p.m. and each aerated withl liter of air per minute and at a temperature of 28C. for forty-seven hours.
  • a silicone anti-foam is added when required.
  • the pH of the fermentation broth rose to 6.8-6.9.
  • Sulfuric acid is added with sterile precautions to restore the pH to 6.5.
  • Example XXVll 0.75 Gram of the product of Example XXVll, as hydrogen maleate, dissolved in 75 ml. of sterile water is added to each of the four ferrnenters and agitation and aeration are continued for a further twenty-three hours.
  • the whole fermentation broths from each fermenter are pooled, the pH adjusted to 8.0 with sodium hydroxide and the 8.2 liters of fermentation broth thus obtained are extracted by agitating vigorously with 16.4 liters of methylene chloride for ten minutes.
  • the solvent extract is dried over anhydrous sodium sulfate and then evaporated to dryness at a temperature below 40C. (dry weight 5.567 g.).
  • a method for the treatment of schistosomiasis which coprises administering to a host infected with schistosomes an effective anti-schistosomicidal amount of a compound selected from the group consisting of substituted 2,3,4,4a,5,6-hexahydro-1H-pyrazino-[1,2- al-quinoline bases of the formula:
  • R is hydrogen, allyl, B-hydroxyethyl or alkyl having from one to four carbon atoms, R is methyl or hydroxymethyl, R is nitro, fluorine, chlorine or bromine located at either the 7- or 9-position of the molecule, R, is hydrogen and R is hydrogen or methyl.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Various 8-methyl and 8-hydroxymethyl-2,3,4,4a,5,6-hexahydro-1Hpyrazino-(1,2-a)-quinolines having either nitro, cyano or halogen substituted at the 7- or 9-position of the molecule and the 3allyl, 3-alkyl having one to five carbon atoms, 3-hydroxyalkyl having two to six carbon atoms, 3-cyanoalkyl having up to six carbon atoms in the alkyl moiety, 3-alkanoyloxyalkyl having from two to six carbon atoms in the oxyalkyl moiety and up to six carbon atoms in the alkanoyl moiety, 3-cycloalkyl having up to six carbon atoms, 3-phenylalkyl having up to three carbon atoms in the alkyl moiety, 3-carboxyalkyl having up to six carbon atoms in the alkyl moiety, 3-alkanoyl having up to six carbon atoms, 3carboxyalkanoyl having up to six carbon atoms, 3-carboxyacrylyl, 3-benzoyl, 3-furoyl, 3-thenoyl, 3-phthaloyl, 3-picolinoyl, 3phenylacetyl, 3-carboxy, 3-carbamoyl, 3-thiocarbamoyl and the 3carbalkoxy having from one to 12 carbon atoms in the alkyl moiety derivatives thereof, their preparation and their utility as antischistosomal agents. Typical members include 7-chloro-8-methyl2,3,4,4a,5,6-hexahydro-1H-pyrazino-(1,2-a)-quinoline and 8hydroxymethyl-9-chloro-2,3,4,4a,5,6-hexahydro-1H-pyrazino-(1,2a)-quinoline.

Description

United States Patent 1 Richards Aug. 13, 1974 HEXAHYDRO PYRAZINOQUINOLINES AS ANTI-SCHISTOSOMAL AGENTS [75] Inventor: Hugh C. Richards, Canterbury,
England 73 Assignee: Pfizer Inc., New York, NY.
22 Filed: July 13, 1973 [21] Appl. No.1 379,009
Related US. Application Data [62] Division of- Ser. No. 789,610, Jan. 7. I969,
OTHER PUBLICATIONS Chemical Abstracts 701475012 (1969) Abstracting S. African Patent 6705,768 issued Feb. 7', 1968.
Primary ExaminerJerome D. Goldberg Attorney, Agent, or FirmConnolly and Hutz 5 7 ABSTRACT Various 8-methyl and S-hydroxymethyl-Z,3,4,4a,5,6-
hexahydrol H-pyrazin0-[ 1,2-a1-quinolines having either nitro, cyano or'halogen substituted at the 7- or 9-position of the molecule and the 3-allyl, 3-alkyl hav ing one to five carbon atoms, 3-hydroxyalkyl having two to six carbon atoms, 3-cyanoalkyl having up to six carbon atoms in the alkyl moiety, 3-alkanoyloxyalkyl having from two to six carbon atoms in the oxyalkyl moiety and up to six carbon atoms in the alkanoyl moiety, 3-cycloalkyl having up to six carbon atoms, 3-phenylalkyl having up to three carbon atoms in the alkyl moiety, 3-carboxyalkyl having up to six carbon atoms in the alkyl moiety, 3-alkanoyl having up to six carbon atoms, 3-carboxyalkanoyl having up to six carbon atoms, 3-carboxyacrylyl, 3-benzoyl, 3-furoyl, 3- thenoyl, 3-phthaloyl, 3-picolinoyl, 3-phenylacetyl, 3- carboxy, 3-carbamoyl, 3-thiocarbamoyl and the 3- carbalkoxy having from one to 12 carbon atoms in the alkyl moiety derivatives thereof, their preparation and their utility as anti-schistosomal agents. Typical members include 7,-chloro-8-methyl-2,3,4,4a,5,6- hexahydrol H-pyra2ino-[ l,2-a]-quinoline and 8- hydroxymethyl-9-chloro-2,3,4,4a,5,6-hexahydro-l H- pyraZino-[ l ,2-a1-quinoline.
11 Claims, N0 Drawings HEXAHYDRO PYRAZINOQUINOLINES AS ANTI-SCHISTOSOMAL AGENTS CROSS REFERENCE TO RELATED APPLICATIONS This application is a division of copending US. Pat. application Ser. No. 789,610, filed Jan. 7, 1969 and now abandoned.
BACKGROUND OF THE INVENTION This invention relates to certain new and useful hexahydro pyrazinoquinoline compounds of principal interest to those in the field of chemotherapy. More particularly, it is concerned with various novel substituted hexahydro pyrazinoquinolines and their non-toxic acid addition salts, which are of especial value in view of their anti-schistosomal properties.
In the past, various attempts have been made by numerous investigators in this particular field of therapy to obtain new and still better forms of agents and/or methods for the treatment of schistosmiasis. In many instances, these efforts have further involved the synthesis and testing of various new organic compounds,
particularly in the category of di-nitrogen heterocycles.
For instance, in British Patent No. 837,306, there is disclosed a series of dicarboxylic acid monopiperazides with a 3-halogen-4-methylphenyl moiety located at the l-position of the piperazine ring that are reported as being active against schistosomiasis. However, little is known about the effect of other nitrogen heterocycles in this area and the existing therapy, unfortunately, still suffers from a number of known drawbacks such as, e.g., relatively low potency (requiring more than a sinto six carbon atoms, carboxyacrylyl, benzoyl, furoyl, thenoyl, phthaloyl, picolinoyl, phenylacetyl, carboxy, carbamoyl, thiocarbamoyl and carbalkoxy having from one to twelve carbon atoms in the alkyl moiety; R is a member selected from the group consisting of methyl, hydroxymethyl and formyl; R is a member selected from the group consisting of nitro, cyano, fluorine, chlorine and bromine located at either the 7- or 9- position of the molecule; and R and R are each a member selected from the group consisting of hydrogen and alkyl having from one to six carbon atoms; and the N-oxide derivatives of said base compounds wherein R is other than hydrogen. These compounds all possess anti-schistosomal activity and are therefore, useful in the treatment of schistosomiasis and/or for the control of schistosome infections.
Of especial interest in this connection are the pre- I ferred compounds of the present invention where R, in
gle dose of therapy), problems of toxicity, the lack of a demonstrated prophylactic effect, etc.
SUMMARY OF THE INVENTION In accordance with the present invention, it has now been surprisingly found that certain novel substituted hexahydro pyrazinoquinoline compounds are extremely useful when employed in the field of drug therapy as anti-schistosomal agents. The novel compounds of this invention are all selected from the group consisting of substituted 2,3,4,4a,5,6-hexahydrol H-pyrazino- [l,2-a]-quinoline bases of the formula:
and the pharmaceutical]y-acceptable acid addition salts thereof, wherein R, is a member selected from the group consisting of hydrogen, allyl, alkyl having from one to five carbon atoms, hydroxyalkyl having from twoto six carbon atoms, cyanoalkyl having up to six carbon atoms in the alkyl moiety, alkanoyloxyalkyl having from two to six carbon atoms in the oxyalkyl moiety and up to six carbon atoms in the alkanoyl moiety, cycloalkyl having up to six carbon atoms, phenylalkyl having up to three carbon atoms in the alkyl moiety, carboxyalkyl having up to six carbon atoms in the alkyl moiety, alkanoyl and carboxyalkanoyl each having up the aforesaid structural formula is either hydrogen or an alkyl group containing from one to four carbon atoms, R is methyl or hydroxymethyl, R is nitro or chlorine located at either the 7- or 9-positions of the molecule, R is hydrogen and R is hydrogen or methyl. Typical member compounds of the preferred class include such 7- or 9-nitro or chloro substituted 8-methyl- 2,3,4,4a,5,6-hexahydrol H-pyrazino-[ 1 ,2-a]- quinolines as 8-methyl-9-nitro-2,3,4,4a,5,6-hexahydrolH-pyrazino-[ l,2-a]-quinoline, 3-n-propyl-8-methyl-9- nitro-2,3 ,4,4a,5 ,6-hexahydro-1H-pyrazino-[ l ,2-a]- quinoline, 3-isopropyl-8-methyl-9-nitro-2,3,4,4a,5,6- hexahydro- 1 H-pyrazino-[ l ,2-a]-quinoline, 7-chloro-8- methyl-2,3 ,4,4a,5,6-hexahydrol H-pyrazino-[ l,2-a]- quinoline, 8-methyl-9-chloro-2,3,4,4a,5,6-hexahydro- 1I-I-pyrazino-[ l,2-a]-quinoline, 3,8-dimethyl-9-chloro- 2,3,4,4a,5,6-hexahydrol l-I-pyrazino-[ l ,2-a]- quinoline, 8,l0-dimethyl-9-chloro-2,3,4,4a,5,6- hexahydro-l H-pyrazino-[ l ,2-a1-quinoline and 3-npropyl-8-methyl-9-chloro-2,3,4,4a,5 ,6-hexahydrol H- pyrazino-[ l ,2-a]-quinoline, respectively, as well as the corresponding 8-hydroxymethyl compounds. These particular compounds are all highly potent as regards anti-schistosomal activity. 1
DETAILED DESCRIPTION OF THE INVENTION In accordance with the processes employed for preparing the novel compounds of this invention, various alternate methods are provided depending upon the specific structures of the actual final products desired. For instance, compounds of the invention in which R is hydrogen, R is methyl and R nitro or halogen are prepared starting from the appropriate 2-aminomethyl- 6-methyll ,2,3 ,4-tetrahydroquinoline compound, which is cyclized with ethyl chloroacetate, chloroacetyl chloride, dimethyl oxalate or oxalyl chloride to give the corresponding 8-methyl-2,3,4,4a,5,6-hexahydro-lI-I- pyrazino-[l,2-a]-quinoline-2-one or 1,2-dione,.as the case may be, followed by reduction with lithium aluminum hydride and then nitration with nitric acid in the presence of concentrated sulfuric acid. The aforementioned 2-aminornethyl-6-methyll ,2,3 ,4- tetrahydroquinoline starting material may beprepared by catalytic reduction of the corresponding 6-methylquinoline-2-aldehyde in the presence of ammonia to give the intermediate 2-aminomethyl-6- methylquinoline, which is then further reduced by catalytic hydrogenation'to afford the desired compound.
In like manner, novel hexahydro pyrazinoquinoline compounds of the same type as indicated above may also be prepared from the aforementioned 2aminomethyl-6-methylquinoline type compounds using bromoacetyl chloride as the cyclizing agent to yield the corresponding 8-methyl-2-oxo-2,3,4-trihydro-lH-pyrazino- [l,2-a]-quinolinium bromide as intermediate, followed by catalytic reduction of the hetero-aromatic ring and lithium aluminum hydride reduction of the keto group to give the corresponding 8-methyl-2,3,4,4a,5,6- hexahydro-l H-pyrazino-[ l ,2-a]-quinoline, which can be nitrated as before. Other routes which may be employed here include (1) the cyclization of known lower alkyl 6-methyll ,2,3 ,4-tetrahydroquinoline-2- carboxylates with ethylene imine, followed by reduction with lithium aluminum hydride and then nitration, and (2) the cyclization of known 2-(5- hydroxyethylamino)methyl-6-methyl-l ,2,3,4- tetrahydroquinolines with phosphorus pentachloride or phosphoric oxide to give the corresponding substituted hexahydro pyrazinoquinoline compound which can then be nitrated. In all instances, the resulting 7- and 9-nitro compounds may be separated, if necessary, by means of fractional crystallization when in the form of a suitable salt.
On the other hand, novel compounds of the present invention in which R is other than hydrogen are simply prepared from those already obtained as aforesaid (where R is hydrogen) by using synthetic methods well-known to those skilled in the art for substitution on the free hydrogen atom of secondary amines. These methods involve such diverse reactions as: (1) acylation to give 3-acyl derivatives; (2) acylation followed by reduction of the carbonyl group to give alkyl or aralkyl substituents; (3) direct alkylation, allylation or aralkylation; (4) reaction with unsaturated or halosubstituted lower alkanoic acids, or with their corresponding esters, amides, thioamides or nitriles; and reaction with lower alkyl chloroformates, or with cyanates, thiocyanates, carbamoyl halides or thiocarbamoyl halides. Needlessto say, such reactions as outlined above can be carried out before the final nitration step (when R is to be nitro), provided said nitration step does not interfere with the aforementioned R substituent.
Alternatively, substituted hexahydropyrazinoquinoline compounds of the invention in which R, is alkyl, hydroxyalkyl, aralkyl or cycloalkyl may be prepared by simply introducing such a group into the Z-aminomethyl or 2-(B-hydroxyethylamino)- methylquinolines or tetrahydroquinoline starting materials, hereinbefore described and utilized for preparing those novel compounds where R is hydrogen. Hence, the substitution step would necessarily be carried out before the cyclization reaction and subsequent nitration in these particular instances. Suitable N- substituted Z-aminomethyl and/or Z-(B-hydroxyethylamino)methyl quinolines and tetrahydroquinolines required as starting materials in this alternate series of reactions may, in turn, be readily prepared starting from the appropriate -methylquinoline-Z-carboxylic acid, 2-halomethyl-6-methylquinoline or -methylquinoline-2-aldehyde, as the case may be, using methods that have previously been described and are illustrated in Examples XXVI-XXX hereinafter.
Of course, when R, is halogen in any of the aforementioned reactions, the final nitration step is omitted.
Needless to say, novel hexahydro pyrazinoquinoline compounds of the invention in which R, is cyano or halogen rather than nitro, as previously described can simply be prepared from the latter (i.e., where R is nitro) by reduction to the amine, followed by diazotisation and subsequent conversion to the 7- or 9-halo or cyano compounds, as the case may be, using wellknown methods of organic chemistry. On the other hand, compounds of the invention in which R is hydroxymethyl or formyl can be prepared from those where R is methyl by using an appropriate microorganism like Aspergillus sclerotiorum Huber, publicly available from the Centralbureau voor Schimmelcultures at Baarn, Netherlands, whereby the methyl group is converted by oxidation to one of the other two groups during the course of the over-all fermentation, as illustrated by Example XXXI hereinafter. The N- oxide derivatives of the compounds of this invention, i.e., N-oxide derivatives of the aforementioned novel substituted hexahydro pyrazinoquinolines in which R, is other than hydrogen, may be prepared by simply using well-known synthetic methods to effect such a conversion from the parent compound, e.g., oxidation via 30 percent hydrogen peroxide or benzoyl peroxide, etc.
Inasmuch as the substituted hexahydro pyrazinoquinoline compounds of this invention all possess an asymmetric carbon atom at position 4A of the molecule, they may exist in separated dand l-optically active forms, as well as in racemic dl-mixtures necessarily produced by the present synthetic methods as hereinbefore described. The invention contemplates the d-, land racemic forms within its scope.
The acids which are used to prepare the pharmaceutical]y-acceptable acid addition salts of this invention are those which form non-toxic acid addition salts containing pharmacologically acceptable anions, such as the hydrochloride and sulfate, when reacted with the aforementioned hexahydro pyrazinoquinoline base compounds. Preferred acids for use in this connection include hydrochloric acid, hydrobromic acid, hydroiodic acid, nitric acid, sulfuric acid. phosphoric acid, acetic acid, lactic acid, citric acid, tartaric acid, oxalic acid, gluconic acid, saccharic acid, benzoic acid, succinic acid, maleic acid, methanesulfonic acid, ethanesulfonic acid, benzene-sulfonic acid, p-toluenesulfonic acid, picric acid, amsonic acid, (4,4- diaminostilbene-2,2-disulfonic acid) and pamoic acid l ,l-methylene-bis-Z-hydroxy-3-naphthoic acid).
As previously indicated, the hexahydro pyrazinoquinoline compounds of this invention are therapeutically valuable as anti-schistosomal agents, particularly in view of their ability to move adult schistosome organisums from their normal sites in the mesenteric veins on to the liver. Hence, they are useful in the treatment of schistosomiasis and/or for the control of schistosome infections with the preferred compounds of this invention being especially useful in this connection in view of the highly potent nature of their anti-schistosomal action and lack of significant side effects. For instance, 3-isopropyl-8-8-methyl-9-nitro- 2,3 ,4,4a,5 ,6-hexahydrol Hpyrazino-[ l ,2-a]-quinoline maleate, a typical and preferred agent of the present invention, has been found to be highly effective against Schistosoma mansoni when administered orally to infected mice at a dosage level of 30 mg./kg. per day for a period of four days without causing any untoward side effects. Further, these herein described compounds can be administered as anti-schistosomal agents by either the oral or parenteral routes of administration. In general, they are ordinarily administered in dosages ranging from about 5.0 mg. to about 150 mg. per kg. of body weight per day, although variations will necessarily occur depending upon the weight and condition of the subject being treated and the particular route of administration chosen.
In connection with the use of the hexahydro pyrazinoquinoline compounds of this invention for the treatment of schistosomiasis, it is to be noted that these compounds may be administered either alone or in combination with pharmaceutically acceptable carriers by either of the two routes previously indicated, and that such administration can be carried out in both single and multiple dosages. More particularly, the novel compounds of this invention can be administered in wide variety of different dosage forms, i.e., they may be combined with various pharmaceutically acceptable inert carriers in the form of tablets, capsules, lozenges, troches, hard candies, powders, sprays, aqueous sus pensions, injectable solutions, elixirs, syrups, and the like. Such carriers include solid diluents or fillers, sterile aqueous media and various non-toxic organic solvents, etc. Moreover, such oral pharmaceutical formulations can be suitably sweetened and/or flavored by means of various agents of the type commonly employed for just such purposes. In general, the therapeutically useful compounds of this invention are present in such dosage forms at concentration levels ranging from about 0.5 to about 90 percent by weight of the total composition, i.e., in amounts which are sufficient to provide the desired unit dosage previously indicated.
For purposes of oral administration, tablets containing various excipients such as sodium citrate, calcium carbonate and dicalcium phosphate may be employed along with various disintegrants such as starch and preferably potato or tapioca starch, alginic acid and certain complex silicates, together with binding agents such as polyvinylpyrrolidone, sucrose, gelatin and acacia. Additionally, lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc are often very useful for tabletting purposes. Solid compositions of a similar type may also include lactose or milk sugar as well as high molecular weight polyethylene glycols. When aqueous suspensions and/or elixirs are desired for oral administration, the essential active ingredient therein may be combined with various sweetening or flavoring agents, coloring matter or dyes and, if so desired, emulsifying and/or suspending agents as well, together with such diluents as water, ethanol, propylene glycol, glycerin and various like combinations thereof.
For purposes of parenteral administration, solutions of these particular hexahydro pyrazinoquinolines in seasame or peanut oil or in aqueous-propylene glycol or N,N-dimethylformamide may be employed, as well as sterile aqueous solutions of the corresponding watersoluble, non-toxic mineral and organic acid addition salts previously enumerated (e.g., the methane sulfonate salt). Such aqueous solutions should be suitably buffered if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose. These particular aqueous solutions are especially suitable for intravenous, intramuscular, subcutaneous and intraperitoneal injection purposes. In this connection, the sterile aqueous media employed are all readily obtainable by standard techniques well-known to those skilled in the art.
This invention is still further illustrated by the following examples, which are not to beconstrued in any way or manner as imposing limitations upon the scope thereof.
EXAMPLE I A solution consisting of 200 g. of l-benzoyl-Z-cyano- 6-methyl 1,2-dihydro-quinoline (prepared by the method of Reissert starting from -methylquinoline and using benzoyl chloride and potassium cyanide as mixture consisting of 90 percent by volume of 5N hydrochloric acid and 10 percent by volume of ethanol, and refluxed overnight for a period of approximately 18 hours. After allowing to cool to room temperature, the resulting mixture was made strongly basic with 5N sodium hydroxide, and the basic solution was thereafter extracted with diethyl ether and filtered. The insoluble material on the filter funnel was then dissolved in 2N hydrochloric acid, treated with alkali as before and extracted with diethyl ether. Thecombined ether extracts from both operations were then dried over anhydrous sodium sulfate and distilled under reduced pressure to give 2-aminomethyl-6-methyl-1,2,3,4- tetrahydroquinoline as a residual oil (b.p. 126140C./0.4 mm. Hg), which subsequently crystallized on standing to afford a solid product melting at 57-6lC.
A finely-ground powdered mixture was then prepared consisting of 8.8 g. (0.05 mole) of 2- aminomethyl-6-methyl-l ,2,3 ,4-tetrahydro-quinoline, obtained as described above, and 11.8 g. (0.10 mole) of dimethyl oxalate. The latter mixture was then heated in an open vessel on the steam bath for a period of 18 hours. The resulting brown mobile oil, obtained in this manner, was allowed to cool before treatment with 20 ml. of acetone. On boiling the latter mixture, followed by cooling, there was finally a white solid material as precipitate. The latter material was then recovered by means of filtration, washed with a little cold acetone and subsequently dried in vacuo to afford the desired product in crude form. Recrystallization from acetone then gave 2.5 g. of pure 8-methyl-2,3,4,4a,5,6- hexahydrol H-pyrazine-[ l ,2-a]-quinoline-1 ,2-dione in the form of colorless needles, mp. 213-216C.
Anal.
Calcd. for C, H N O C, 67.80; H, 6.10; N, 12.15.
Found: C, 67.70; H, 6.10; N, 12.20.
The entire yield of 8-methyl-2,3,4,4a,5, 6-hexahydro- 1H-pyrazino-[l,2-a]-quinoline was next added portion wise to a slurry consisting of 1.1 g. of lithium aluminum hydride in 100 ml. of dry dioxane at a temperature kept within the 7583C. range. Upon completion of this step, the mixture was stirred vigorously for eight hours and then allowed to cool slowly to approximately 35C. At this point, water was carefully added to destroy excess hydride in the mixture and the crude product ma terial was then poured into water and subsequently extracted from the resulting aqueous medium with diethyl ether (three separate extractions were necessary). After drying the ether extracts over anhydrous magnesium sulfate, followed by evaporation of same under pressure, there was finally obtained 1.8 g. of crude 8- methyl-2,3 ,4,4a,5,6-hexahydrol H-pyrazino-[ 1,2-a1- quinoline as a brown mobile oil. Subsequently distillation of the latter material in vacuo then gave 1.15 g. of pure product, which was a red viscous oil (b.p. 150C./ 1 mm. Hg.). Conversion of this material to the maleate derivative, for analytical purposes, then gave pure 8-methyl-2,3,4,4a,5 ,6-hexahydrol H-pyrazino- [l,2-a]-quinoline maleate, m.p. l57l58C. Anal. 1
Calcd. for C H N O C, 64.15; H, 6.90; N, 8.80.
Found: C, 64.15; H, 6.80; N, 8.75.
A solution consisting of 0.315 g. of concentrated nitric acid (d. 1.5) in 5 ml. of concentrated sulfuric acid was then prepared and added to a well-stirred, ice cold solution of 1.15 g. of 8-methyl-2,3,4,4a,5,6-hexahydrolH-pyrazine-[1,2-a]-quinoline in 25 ml. of concentrated sulfuric acid. The resulting mixture was then stirred at 5C. for an additional period of 45 hours. The crude nitrated product was poured into a mixture of ice and water, and subsequently made basic with solid potassium carbonate and filtered. Upon extraction of the combined chloroform extracts under reduced pressure, there was ultimately obtained a 1.0 g. yield of an orange-red oil as the residual liquid. The latter-material, which was essentially pure 8-methyl-9- nitro-2,3,4,4a,5,-hexahydro-1H-pyrazino-[ 1,2-a]- quinoline, was then taken up in ml. of ethyl acetate and mixed with a solution of 0.5 g. of maleic acid dissolved in 5 ml. of warm ethyl acetate. In this manner, there was obtained a canary yellow precipitate of the maleate salt, which was subsequently filtered and re crystallized from hot methanol to give 0.7 g. of pure 8-methyl-9-nitro-2,3 ,4,4a,5 ,6 -hexahydro-1H- pyrazino-[ l,2 a]-quinoline maleate in the form of golden yellow plates, m.p. 203204C.
Anal.
Calcd. for C1 H21N O :C, 56.20; H, 5.80; N, 11.60.
Found: c, 56.45 H, 5.80; N, 11.85.
" EXAMPLE 1] To a warm solution of 42 g. methylquinoline in 200 ml. of ethanol, there were added g. of ethanolamine in a cautious manner in view of the exothermic nature of the reaction. The resulting mixture was then refluxed for a period of two hours and 1 g. of activated charcoal was thereafter added. Refluxing was then continued for an additional five minutes before filtering the mixture while hot. On slow cooling of the filtrate to 0C., there was ultimately obtained a 48.6 g. yield of 2-(B- hydroxyethyliminomethyl)-6-methylquinoline in the form of small white needles, mp. l47-l49C.
A solution consisting of 45 g. of 2-(B- hydroxyethyliminomethyl)-6-methylquinoline in 500 of 2-formyl-6- 8 ml. of absolute ethanol was then prepared and subsequently hydrogenated over Raney Nickel (5 g.) at C. and 750 p.s.i.g. pressure for a period of seven hours. After removal of the catalyst by means of filtration and the solvent by means of evaporation under reduced pressure, there was obtained a pale yellow oil which soon solidified on standing. Recrystallization of the latter material from ethyl acetate then gave 32.5 g. of 2-(B-hydroxyethylaminomethyl)-6-methyl-l2,3,4- tetrahydroquinoline as a white solid, mp. 8888.5C.
The product obtained above, i.e., 23.4 g. of the material melting at 8888.5C., was then dissolved in 250 ml. of dry xylene and the resulting solution stirred vigorously while 48 g. of phosphoric oxide was rapidly added thereto, being washed into the reaction mixture was a further quantity of dry xylene (150 ml.). The stirred solution was then gradually heated to C. during a two and one-half hour period and refluxed at that point for a further 24 hours. The spent mixture was then cooled and the xylene solution removed therefrom by means of decantation. Upon evaporation of the solvent under reduced pressure, a semisolid residual material was obtained. The latter was then continually extracted with 5N hydrochloric acid until the extracts were no longer colored, and the combined extracts were subsequently basified with 5N sodium hydroxide solution before further extraction with three separate portions of diethyl ether (each of 250 ml. in volume). The combined ether extracts were again dried over anhydrous magnesium sulfate and filtered, with the filtrate being thereafter evaporated to yield a dark viscous oil. Fractional distillation of the latter material ture was then refluxed for a period of 18 hours (the water which formed was collected in a Dean-Stark apparatus). An additional amount (4.0 ml.) of formic acid was then added and the mixture refluxed for a further 24 hours, before cooling to room temperature (-25C. After extracting with two- 50 ml. portions of 2N hydrochloric acid and washing the combined extracts with diethyl ether, followed by basification of same with 2N sodium hydroxide solution, there was obtained a basic aqueous medium which was subsequently extracted with two-100 ml. portions of ethyl acetate. The combined organic extracts were then dried over anhydrous magnesium sulfate and filtered, and the resulting filtrate evaporated to near dryness under reduced pressure to afford an almost-white solid material. The latter material was then taken up in 20 ml. of chloroform and the resulting solution diluted with 20 ml. of petroleum ether (b.p. 4060C.) to give 4.4 g. of 3-formyl-8-methyl-2,3,4,4a,5,6-hexahydrolH-pyrazino-[ l ,2-al-quinoline as a white solid precipitate, m.p. ll5l 16C.
A solution of 4.2 g. of the above product in 100 ml. of dry dioxane was then prepared and this solution was added to a rapidly-stirred suspension of 5 g. of lithium aluminum hydride in ml. of dry dioxane over a 45- minute period. The resulting mixture was stirred for 5.5 hours, cooled and the excess reagent cautiously decomposed by the slow addition of water thereto. After removing solid impurities present by means of filtration and evaporating the resulting filtrate to near dryness while under vacuum (with the last traces of water being removed by means of azeotropic distillation with benzene), there was obtained a residual material which soon solidified on cooling. Subsequent recrystallization from petroleum ether (b.p. 4060C.) then gave 2.9 g. of 3,8-dimethyl-2,3,4,4a,5,6-hexahydro-lH-pyrazino- [1,2-a]-quinoline as colorless prisms melting at The above compound (2.5 g.) was then dissolved in 30 ml. of concentrated sulfuric acid by adding same to said acid over a one-hour period and then stirring the mixture at C. until complete dissolution occurred. At this point, a solution consisting of 0.715 g. of nitric acid (d. 1.5), i.e., 0.48 ml., in m1. of concentrated sulfuric acid was slowly added thereto during the course of a twenty-minute period, with constant agitation, while maintaining the temperature of the reaction mixture at 0-5C. throughout the course of the addition step. After stirring the reaction mixture for a further three hours at 05C., the solution was poured into ice and subsequently neutralized with sodium carbonate reagent. The product separated as a red-orange oil, together with some sodium sulfate crystals, and was collected by filtering and washing with chloroform. The chloroform layer was then separated and the aqueous layer extracted. with another portion of chloroform. The combined chloroform extracts were then dried over anhydrous magnesium sulfate, filtered and the filtrate subsequently evaporated to afford a red-orange oil. The latter material which was essentially pure 3,8- dimethyl-9-nitro-2,3 ,4,4a,5 ,6-hexahydro-l H-pyrazino- [1,2-a]-quinoline, was then taken up in a minimum amount of ethyl acetate and added to a hot solution of 1.5 g. of maleic acid dissolved in 30 ml. of ethyl acetate. After cooling to room temperature and adding 50 ml. of dry diethyl ether to effect complete precipitation, the resulting solid was collected by means of filtration and recrystallized from ethyl acetate-methanol (4:1 by volume) to give 1.8 g. of 3,8-dimethyl-9-nitro- 2,3,4,4a,5,6-hexahydro-l l-l-pyrazino-[ 1 ,2-a1-quinoline maleate as a yellow crystalline material, m.p. 182185C. Anal.
Calcd. for C H, N O -C H O C, 57.31; H, 6.00 N,
11.14. Found: C, 57.16; H, 6.21; N, 10.46.
EXAMPLE Ill A mixture consisting of 5.0 g. of 8-methyl- 2,3,4,4a,5,6-hexahydro-1H-pyrazino-[ 1 ,2-a]-quino1ine in 25 ml. of acetic anhydride was refluxed for a two and one-half hour period, and the resulting dark solution was then poured into ice-water (250 ml.). After allowing the precipitated solid to stand for one hour in the aqueous medium, it was subsequently extracted with two-200 ml. portions of ethyl acetate. The combined extracts were then washed with 10 percent sodium bicarbonate solution, followed by water and dried over anhydrous magnesium sulfate. On removal of the drying agent by means of filtration and the solvent by means of evaporation under reduced pressure, there was obtained a residual pink solid. Recrystallization of the latter material from petroleum ether (b.p. 6080C.) then gave 3.92 g. of 2-acetyl-8-methyl- 2,3 ,4,4a,5,6-hexahydro-1 l-l-pyrazino-[ 1,2-a]-quinoline as white prisms melting at 127218C.
The above product (3.5 g.) was then reduced by lithium aluminum hydride in the manner of the previous example and after purification by distillation under reduced pressure, there was obtained a 2.0 g. yield of 3- ethyl-8-methyl-2,3,4,4a,5,6-hexahydro-1H-pyrazino- [1,2-a]-quinoline (b.p. 130C. /0.30 mm. Hg), which soon solidified to give a colorless material of melting point 5657C.
Nitration of 1.98 g. of 3-ethyl-8-methyl-2,3,4,4a,5,6- hexahydro-lH-pyrazino-[1,2-a]-quinoline was then carried out with nitric-sulfuric acid as reagent in the same manner as described in the previous example for the nitration of the corresponding 3,8-dimethyl compound. In this particular case, the product obtained was 3-ethyl-8-methyl-9-nitro-2 ,3 ,4,4a,5 ,6-hexahydro-1H- pyrazino-[1,2-a]-quinoline, which after conversion to the maleate and recrystallization from ethyl acetatemethanol (10:1by volume) gave 1.0 g. of pure 3-ethy1- 8-methyl-9-nitro-2,3 ,4,4a,5 ,6-hexahydro- 1 l-l-pyrazino- [1,2-a]-quinoline maleate in the form of yellow needles, m.p. 172173C.
Anal.
Calcd. fOr C15H21N3O2' C4H4O4: C, H, N,
10.74. Found: C, 58.54; H, 6.50; N, 11.26.
Example W A solution consisting of 10 g. of 2-chloromethyl-6- methyl-quinoline and 16.2 g. of N- isopropylaminoethanol dissolved in 100 ml. of absolute ethanol was refluxed for a period of six hours. The alcohol solvent was then removed in vacuo and the residual oil basified with 2N sodium hydroxide solution, followed by subsequent extraction with chloroform. The combined chloroform extracts were dried over anhydrous magnesium sulfate, filtered and the resulting filtrate evaporated under reduced pressure to give a black viscous oil, which on subsequent distillation afforded 9.4 g. of 2-N-(B-hydroxyethyl)-N- isopropylaminomethyl-6-methylquinoline as a thick red oil, b.p. l55-l58C./0.25 mm. Hg.
A solution of 8 g. of the above product in 100 ml. of absolute ethanol was then hydrogenated over 3 g. of Raney Nickel at C. and 750 p.s.i.g. pressure for a period of 3.5 hours. After removal of the catalyst by means of filtration and the alcohol solvent on evaporation in vacuo, there was obtained a 7.2 g. yield of 2-N- (B-hydroxyethyl)-N-isopropylaminomethyl-6-methyll,2,3,4-tetrahydroquinoline in the form of a green viscous oil.
To a well-stirred solution consisting of 6.1 g. of 2-N- (B-hydroxyethyl )-N-isopropylaminomethyl-6-methyll,2,3,4-tetrahydroquinoline in ml. of dry xylene, there were added 10.6 g. of phosphoric oxide and the resulting mixture heated to reflux during the course of a two and one-half hour period. After refluxing for a further ten hours, the mixture was cooled and the xylene subsequently removed therefrom by decantation. The resulting semi-solid mass was then dissolved in 5N hydrochloric acid, and thereafter basified with 5N sodium hydroxide solution before extraction with diethyl ether. The dried ethereal extracts were then evaporated to near dryness under reduced pressure to give a black oil residue, which on subsequent distillation in vacuo afforded 1.3 g. of 3-isopropyl-8-methyl- 2,3,4,4a,5,6-hexahydro-11-1-pyrazino-[ l ,2-a]-quinoline in the form ofa colorless oil, b.p. 156160C./1.0 mm. Hg.
To 1.05 g. of the above product in 20 ml. of concentrated sulfuric acid at C., there were added 1.18 ml. of fuming nitric acid in 2.0 ml. of concentrated sulfuric acid at 03C., with constant agitation being maintained throughout the addition step which required approximately 1.5 hours. The resulting mixture was then stirred at 0-3C. for a period of four hours, before pouring into crushed ice and basifying with solid potassium carbonate. The oily product so obtained was thereafter extracted with chloroform and the combined chloroform extracts were subsequently dried and evaporated under reduced pressure to a brown oil of 1.5 g. yield. The latter material was dissolved in 5 ml. of ethyl acetate and then treated with a warm solution of maleic acid in ethyl acetate (0.6 g. of said acid in 5 ml. of solvent),to give a canary' yellow solid as precipitate. Recrystallization of the latter material from hot ethyl acetate-methanol (:1 by volume) afforded 0.7 g. of 3- isopropyl-8-methy1-9-nitro-2,3,4,4a,5,6-hexahydro- 11-l-pyrazino-[1,2-a]-quinoline maleate in the form of golden yellow needles, mp. l49-150C.
Anal.
Calcd. for cud 123N302 C4H404i C. H.
7.77; N, 7.83. Found: C, 66.41; H, 7.44; N, 7.83.
EXAMPLE V The procedure described in Example 111 was repeated except that propionic anhydride was substituted for acetic anhydride as reagent in the first stage and there was ultimately obtained, in this manner, a 0.9 g. yield of 3-n-propyl-8-methyl-9-nitro-2,3,4,4a,5,6- hexahydro-1H-pyrazino-[ 1 ,2-a]-quinoline maleate in the form of a yellow-brown powder, m.p. 169-170C.
Anal.
Calcd. for C16H23N3O2'C4H4O4: C, H, N,
10.37. Found: C, 59.39; H, 6.69; N, 10.41.
EXAMPLE VI Anal.
Calcdf0! C17H25N3O2'C4H O4i C, H, N,
10.02. Found: C, 60.66; H, 7.05; N, 9.98.
EXAMPLE V11 The procedure describedin Example IV was repeated except that N-cyclohexylethanolamine was employed as reagent in the first step instead of N- isopropylaminoethanol and there was obtained 2-N- cyclohexyl-N-hydroxyethylaminomethyl-6-methylquinoline as the resultant product. The latter was then reduced with Raney nickel, in the manner of Example 1V, to give 2-N- cyclohexyl-N-B- hydroxyethylaminomethyl-6-methyl-l ,2,3 ,4-
tetrahydroquinoline, isolated as the maleate salt, m.p. 170l72C. Cyclization with phosphoric oxide, as in the aforesaid example, then afforded a 50 percent yield of 3-cyclohexyl-8-methyl-2,3,4,42,5,6-hexahydro-1H- pyrazino-[ l ,2-a]-quinoline maleate (m.p. l72.4-174C.), which was subsequently converted to 3-cyclohexyl-8-methyl-9-nitro-2,3,4,42,5,6-hexahydrolHpyrazino-[1,2-a[-quinoline maleate in a 1.2 g. yield. The latter product was obtained in the form of yellowish-brown needles, mp. 2132l4C. after recrystallization from ethanol-ethyl cellusolve (20:1 by volume).
Anal.
Calcd. for C19Hg7N30g C4H4O4I C. H.
7.01: N, 9.43. Found: C, 61.72; H, 7.04; N, 9.29.
EXAMPLE V111 A solution consisting of 0.78 g. of 8-methyl-9-nitro- 2,3,4,4a,-5,6-hexahydro-1H-pyrazino-[ l,2-a]- quinoline in 20 ml. of dry benzene containing 0.29 g. of triethylamine was stirred at 0C. in an ice-water bath, while 0.3 g. of ethyl chloroformate dissolved in 5 ml. of dry benzene was slowly added thereto during the course of a 30-minute period. The resulting mixture was then stirred for an additional two hours at ambient temperatures, filtered and the residue washed dry with diethyl ether. The combined washings and filtrate were then evaporated to near dryness under reduced pressure and the residual oil so obtained soon solidified. Recrystallization of the latter material from petroleum ether (b.p. l00C.) then gave 0.60 g. of 3- ethoxycarbonyl-8-methyl-9-nitro-2,3,4,4a,5,6- hexahydro-l H-pyrazino-[ l,2-a]-quinoline as yellow rosettes, m.p. C.
Anal.
Calcd. for C 5H2 N3O4i C,
bright Found: C, 60.20; H, 6.87; N, 12.77.
EXAMPLE IX A solution of 1 1.5 g. of 8-methyl-9-nitro- 2,3,4,4a,5,6-hexahydro-1H-pyrazino-[ l,2-a]-quinoline in m1. of acetic anhydride was refluxed for a period of two hours. The solution was then cooled and poured unto 500 g. of ice. In this way, the product crystallized on standing and was subsequently collected by means of suction filtration. After thoroughly washing the filter cake with water to remove excess acetic acid from same, the product was recrystallized from ethanol to afford 10.5 g. of pure 3-acetyl-8-methyl-9-nitro- 2,3,4,4a,5,6-hexahydro-1H-pyrazino-[1,2-a]- quinoline, m.p. 137-139C.
Anal.
Calcd. for G l-1 N 0 C, 62.26; H, 6.62; N, 14.52. Found: C, 62.15; H, 6.55; N, 14.39.
EXAMPLE X A solution consisting of 0.80 g. of 3,8'-dimethyl-9- nitro-2,3,4,42,5,6-hexahydro-1H-pyrazino-[1,2-a]- quinoline dissolved in ml. of ethanol was hydrogenated over 80 mg. of 10 percent palladium-on-charcoal catalyst at 25C. and 100 p.s.i.g. pressure of hydrogen for a period of 3.5 hours. The catalyst was then removed by means of filtration and the solvent evaporated under reduced pressure to afford 3,8-dimethyl-9- amino-2,3 ,4,4a,5 ,6-hexahydrol H-pyrazino-[ 1 ,2-a]- quinoline as a brown residual oil. The latter material, which was viscous in nature, was then dissolved in 1.3 ml. of concentrated hydrochloric acid and 1 g. of ice and subsequently treated a solution of 180 mg. of sodium nitrite in 1.0 ml. of water while at C. The solution of the diazonium salt was then added at 0C. to a solution of freshly prepared cuprous chloride in 1.3 ml. of concentrated hydrochloric acid. The cuprous chloride had previously been obtained by mixing hot aqueous solutions of cupric sulfate (0.84 g.) and sodium chloride (0.22 g.) in 3.0 ml. of water, and thereafter washing the resulting pale green precipitate by means of decantation. At any rate, the resulting brown aqueous suspension, obtained as indicated above, was subsequentlyv stirred and allowed to warm very slowly to room temperature 25C.), at which point it was then heated to 60C. via a steam-bath and allowed to cool once again. The resulting solution was then basified with 5N sodium hydroxide solution, extracted with diethyl ether and the combined ether extracts subsequently dried over anhydrous magnesium sulfate. Upon removal of the ether solvent by means of evaporation under reduced pressure, there was obtained 0.4 g. of a brown oil as the residual liquid. The latter material was then chromatographed on neutral alumina, using chloroform as the eluent, to afford 150 mg. of a pale yellow oil, which consisted essentially of pure 3,8-dimethyl-9- chloro-2,3,4,4a,5,6-hexahydro-lH-pyrazino-[ 1 ,2-a]- quinoline. Treatment of this compound in the usual manner with one equivalent of maleic acid, dissolved in warm ethyl acetate, then gave the corresponding maleate salt. Upon subsequent recrystallization of the latter material three times from ethyl acetate, there was finally obtained 100 mg. of pure 3,8-dimethyl-9-chloro- 2,3 ,4,4a,5 ,6-hexahydro- 1 H-pyrazino-[ 1 ,2-a]-quinoline maleate. in the form of small white crystals, m.p. 170-171C. (decomp.). Anal.
calcd. for C14H1QCIN2'C4H4O4I C, H, N,
7.64. Found: C, 59.11; H, 6.42; N, 7.41.
EXAMPLE XI yield of 3-acetyl-8methyl-9-amino-2,3,4,4a,5,6- hexahydro-lH-pyrazino-[1,2-a]-quinoline, m.p. 197-- 1 99C.
The above product (5.0 g.) was then diazotized and treated with cuprous chloride in the same manner as described in the previous example for the corresponding 3-methyl compound. After basification with 5N so dium hydroxide solution, the resulting product was extracted into chloroform and the chloroform extracts subsequently washed with water, dried over anhydrous magnesium sulfate and filtered. The chloroform filtrate was then concentrated in vacuo and the residual oil so obtained (essentially, crude 8-methyl-9-chloro- 2,3,4,4a,5,6-hexahydro-1H-pyrazino-[ l,2-a]- quinoline) was taken up in a small amount of ethyl acetate. Treatment of the latter solution with a solution of maleic acid dissolved in ethyl acetate, then gave 8- methyl-9-chloro-2,3,4,42,5,6-hexahydro-1H-pyrazino- [1,2-a]-quinoline maleate as a crystalline precipitate. Recrystallization of the latter material from ethanol, after first washing with a fresh portion of ethyl acetate solvent by decantation, then afforded the pure maleate salt in 0.5 g. yield (m.p. 325C. with decomp. above 250C) On subsequent conversion to the corresponding hydrochloride and further recrystallization from ethanol, there was ultimately obtained pure 8-methyl- 9-chloro-2,3,4,4a,5,6-hexahydro-1H-pyrazino-[1,2-a]- quinoline hydrochloride (m.p. 325C. with decomp.
above 260C).
Anal.
Calcd. for C H Cl N z C, 57.1; H, 6.64; N, 9.82. Found: C, 57.05; H, 6.90; N, 9.82.
EXAMPLE XII A solution consisting of g. of 2,6-dimethyl-5- chloroquinoline dissolved in 600 ml. of dioxane was added rapidly to a well-stirred solution of selenium dioxide (60 g.) in a mixture of 500 ml. of dioxane and 24 ml. of water. The resulting mixture was then stirred and refluxed for a period of three hours, followed by cooling to room temperature and subsequent extraction with chloroform. The combined chloroform extracts were then dried over anhydrous magnesium sulfate and filtered, and the resulting filtrate thereafter concentrated in vacuo to afford a solid residue. Recrystallization of the latter material from ethyl acetate, in the presence of charcoal, then gave 55 g. of 5-chloro-6- methylquinoline-Z-aldehyde as orange needles, mp. 172l73C. The above aldehyde product (53 g.) was then dissolved in 750 ml. of boiling absolute ethanol and treated with 16 g. of ethanolamine, followed by continued boiling for a period of two hours. At this point, the resulting mixture was cooled and the precipitate subsequently removed by means of filtration to afford crude product. Upon recrystallization from percent ethanol (1500 ml.), there was obtained pure 2-(B- hydroxyethyliminomethyl)-5-chloro- 6-methylquinoline, m.p. l76l77C.
The latter product in two liters of ethanol was then treated with 40 g. of sodium borohydride, with stirring and boiling under reflux, the borohydride reagent being added portion-wise over a period of 15 minutes. The resulting solution was then boiled under reflux for a further period of 3.5 hours, cooled and the excess borohydride thereafter decomposed by the addition of 250 ml. of 5N hydrochloric acid. After concentrating in vacuo, the solid residue so obtained was suspended in water and made alkaline with sodium hydroxide solution prior to extraction into chloroform. The chloroform solution was then washed with water, dried over anhydrous magnesium sulfate and filtered. Evaporation of the resulting filtrate to near dryness while under reduced pressure then gave a solid residue, which was subsequently dissolved in a liter of ethanol and then treated with 50 ml. of concentrated hydrochloric acid. In this way, the product soon crystallized and was subsequently collected by means of filtration, washed with a little fresh ethanol and then dried to constant weight to afford 43 g. of 2-(B-hydroxyethylaminomethyl)-5- chloro-6-methylquinoline as the dihydrochloride salt, m.p. 193l96C.
A solution consisting of 5 g. of the above product in 250 ml. of water was treated with Adams platinum oxide catalyst (0.2 g.) and hydrogenated at 25C. under a pressure of 30 p.s.i.g. of hydrogen for a period of 5.5 hours. The solution was then filtered to remove the catalyst and the filtrate subsequently made alkaline by the addition of aqueous sodium hydroxide solution. The product then separated from the solution as a gummy solid, which was thereafter extracted into chloroform. The chloroform extract thus obtained was washed with water and dried over anhydrous magnesium sulfate, and the subsequently dry filtrate thereafter concentrated in vacuo to afford a solid residue. Crystallization of the latter material from petroleum ether (b.p. 80100C.) then gave 3.2 g. of 2-(,B-hydroxyethylaminomethyl)- 5-chloro-6-methyl-l ,2,3 ,4-tetrahydroquinoline, m.p. l l9-122C.
A solution of 2.0 g. of 2-(B- hydroxyethylaminomethyl )-5-chloro-6-methyl-l ,2,3 ,4- tetrahydroquinoline dissolved in 40 ml. of dry xylene was treated with 3.55 g. of phosphorus pentachloride and 2 g. of filter-aid. The mixture was then vigorously stirred and boiled under reflux for a period of 24 hours. At the end of this period, the resulting mixture was cooled and slowly acidified with 500 ml. of 2N hydrochloric acid. As soon as all the black tarry residue had dissolved, the acidified mixture was filtered and extracted with diethyl ether. The aqueous solution which remained was then made alkaline with aqueous sodium hydroxide and extracted with diethyl ether once again. The combined ethereal extracts were washed with water, dried in the usual manner and subsequently concentrated in vacuo to afford a solid residual material, which consisted essentially of crude 7-chloro-8-methyl- 2,3,4,4a,5 ,6-hexahydrol H-pyrazino-[ l,2-a]-quinoline. Conversion of the latter material to the maleate salt, followed by recrystallization from ethanol, then gave pure 7-chloro-8-methyl-2,3,4,4a,5,6-hexahydro-lH- pyrazino-[1,2-a]-quinoline maleate, m.p. 189190C.
Anal.
Calcd. for CI3HI7CINZ'C4H4O4I C, H, N,
7.94. Found: C, 57.75; H, 5.94; N, 7.66.
EXAMPLE Xlll Following the procedure described in the previous example, 2,6,S-trimethyl-7-chloroquinoline was converted to 2-forrnyl-6,8-dimethyl-7-chloroquinoline to give a white solid material, melting at 147l50C. after recrystallization from methanol. The latter prodnot was then treated with ethanolamine in accordance with the same procedure and there was obtained 2-(B- hydroxyethyliminomethyl)-6,8-dimethyl-7- chloroquinoline as fawn plates, m.p. 122-123C. after recrystallization from methanol. Conversion of this material (3.6 g.) to the saturated product via hydrogenation over Raney nickel (1 ml. suspension) at 75C. and 750 p.s.i.g. pressure for a period of 0.75 hours, then gave 2.4 g. of 2-(B-hydroxyethylaminomethyl)-6,8- dimethyl-7-chloro- 1 ,2,3 ,4-tetrahydroquinoline as an off-white solid, m.p. l09ll1C. Subsequent treatment of this latter product with phosphorus pentachloride, in the manner of Example XII, then afforded a 40 percent yield of 8,l0-dimethyl-9-chl0ro-2,3,4,42,5,6- hexahydro-lH-pyrazino-[1,2-a]-quinoline as a white powder, m.p. 94 96C. after recrystallization from methanol. Anal.
Calcd. for C H CIN C, 67.06; H, 7.59; N, 11.18.
Found: C, 66.76; H, 7.39; N, 11.20.
EXAMPLE XIV A solution consisting of 1.6 g. of 8-methyl-9-nitro- 2,3,4,4a,5,6-hexahydro-l H-pyrazino-[ l ,2-a]-quinoline dissolved in 20 ml. of dry benzene was treated with 0.7 g. of maleic anhydride dissolved in an equal amount of dry benzene (20 ml.). After allowing the reaction mixture to stand for two minutes at room temperature, a small amount of dark green oil formed and the solution was immediately separated from same by means of decantation. Soon afterwards, a deposit of yellow crystals formed from said solution and the entire mixture was then allowed to stand overnight at room temperature (=25C.) for approximately 16 hours. The yellow crystals were subsequently collected by means of suction filtration and thereafter dried in vacuo to give 1.56 g. of 4-( 8-methyl-9-nitro-2,3 ,4,4a,5 ,6-hexahydro-l H- pyrazino-[ l,2-a]-quino1ine-3-y1)-4-oxocrotonic acid, m.p. 150l52C.
Anal.
Calcd. for C H,,,N O C, 59.12; H, 5.55; N, 12.17. Found: C, 58.80; H, 5.61; N, 11.72.
EXAMPLE XV A solution of 2.0 g. of 8-methyl-2,3,4,4a,5,6-hexahydro-1H-pyrazino[ l,2-al-quinoline in ml. of absolute ethanol was treated with 2 ml. of l-bromo-3- methylbutane and 2 g. of sodium carbonate, and the resulting mixture was stirred and refluxed for 24 hours. After cooling to room temperature and adding 200 ml. of dry diethyl ether to the mixture, the latter was filtered and the filtrate subsequently evaporated under reduced pressure to give an oily material as residue. The latter material was then taken up in 50 ml. of ethyl acetate, filtered again and the filtrate treated with a hot solution of 1.2 g. of maleic acid dissolved in ethyl acetate. On cooling, the resulting crystalline precipitate was collected by means of filtration and air-dried to give a 3.45 g. yield of 3-(3-methylbutyl)-8-methyl- 2,3,4,4a,5,6-hexahydro-1H-pyrazino-[1,2-a]-quinoline maleate, m.p. 169170C.
The above product (3.4 g.) was then shaken between 200 m1. of 2N sodium hydroxide solution and 100 ml. of diethyl ether, and the ether layer subsequently separated, dried over anhydrous magnesium sulfate and filtered. The resulting filtrate was then evaporated under reduced pressure to give 2.0 g. of 3-(3-methylbutyl)-8- methyl-2,3,4,4a,5,6-hexahydro-1H-pyrazino-[ l,2-a]- quinoline as the residual oil. After nitration of the latter substance in the manner of Example 11 and subsequent conversion to the maleate, there was obtained 1.6 g. of 3-(3-methylbutyl)-8-methyl-9-nitro-2,3,4,4a,5,6- hexahydro-l H-pyrazino-[ l ,2-a]-quinoline maleate in the form of fluffy, bright-yellow needles, m.p. 2l3214C. after recrystallization from ethyl acetateethyl cellusolve (9:1 by volume).
Anal.
17 Calcd. for c,,,H,,N o,-c,n,o.,: c, 60.95; 11,7.21;
61,969. Found: c, 60.75; H, 7.16; n, 9.48.
EXAMPLE XVI A solution consisting of 800 mg. of 8-methyl-9- chloro-2,3,4,4a,5,6-hexahydro-l H-pyraZino-[ l ,2-a]- quinoline dissolved in 60 ml. of absolute ethanol was treated with 0.46 ml. of n-propyl bromide and 800 mg. of potassium carbonate and then refluxed for a period of three days. At the end of this time, two further quantities of n-propyl bromide (0.2 ml. each) in absolute ethanol (2 ml.) were added at three-day invervals and after a period of nine days, thin-layer chromatography indicated that the reaction was substantially complete. The excess potassium carbonate was then removed from the mixture by means of filtration and the ethanol solvent via evaporation under reduced pressure. Treatment of the residue with water and a few ml. of 5N sodium hydroxide to ensure complete basification, then gave an aqueous solution that was subsequently extracted with diethyl ether. The combined ethereal extracts were then dried over anhydrous magnesium sulfate, filtered and the filtrate concentrated in vacuo to yield 0.4 g. of a brown oil, which was essentially pure 3-n-propyl-8-methyl-9-chloro-2,3,4,4a,5,6-hexahydroll-I-pyrazino-[1,2-a]-quinoline. This product was then converted to the maleate salt'in the usual manner, using 250 mg. of maleic acid in the ethyl acetate as the reagent. After recrystallization from ethyl acetate, there was obtained 200 mg. of pure 3-n-propyl-8-methyl-9- chloro'2,3 ,4 ,4a,5,6-hexahydro-l H-pyrazino- [l,2-a]-quinoline maleate, m.p. 149-l50C.
Anal.
Calcd. fOr C1 H23ClN2'C4H404: C, 7.10. Found: C, 60.82; H, 6.73; N, 6.94.
EXAMPLE XVII A solution consisting of 2.47 g. of 8-methyl-9-nitro- 2,3,4,4a,5 ,6-hexahydro-l H-pyrazino-[ 1,2-a]-quinoline dissolved in 2.5 ml. of acetic anhydride was heated to l-l25C. in an oil-bath. To this solution, there was then added 1.06 g. of acrylonitrile in a dropwise manner over a two-hour period and the resulting darksolution was thereafter refluxed for three hours (using an oil bath temperature of ca. 134C). The reaction mixture was then allowed to cool to room temperature and made alkaline with a saturated solution of potassium carbonate in water. The basified aqueous solution was next extracted with two-75 ml. portions of chloroform and the chloroform extracts were subsequently dried over anhydrous magnesium sulfate, filtered and thereafter concentrated in vacuo to yield a dark-red oil as residual liquid. The latter substance was taken up in ethanol, whereby a yellow crystalline material soon deposited from said solution. After collecting the crystals by means of filtration and recrystallizing same from ethanol, there was finally obtained a 1.2 g. yield of 3- (fi-cyanoethyl)-8-methyl-9-nitro-2,3,4,4a,5,6-hexahydro-lI-I-pyrazino-[ l ,2-al-quinoline in the form of small yellow-brown crystals, m.p. 1lll 12C. (with softening at 100C.). Anal.
Calcd. for C, H N O C, 64.00; H, 6.67; N, 18.67.
Found: C, 64.15; H, 6.73; N, 18.75.
EXAMPLE xvni A culture of Aspergillus Sclerotiorum Huber is grown in several 300 ml. Erlenmeyer flasks each containing 50 ml. aliquots of the hereinafter more fully described soybean-glucose nutrient medium, which had previously been sterilized via an autoclave at 15 p.s.i.g. pressure for a period of 35 minutes. After shaking at 28C. for a period of 24 hours, via a shaker apparatus rotating at approximately 230 rpm, the resulting incolum is added (at a level of 7.5 percent by volume) under sterile conditions and with constant agitation to a fermenter pot containing two liters of said same nutrient medium having the following composition:
Grams Soybean meal Glucose 20 Sodium chloride 5 Potassium hydrogen phosphate 5 Yeast extract 5 Tap water, in sufficient amount for a 1000 ml. solution, adjusted to pH 6.5 with concentrated sulfuric acid.
The inoculated medium in the fermenter is then agitated at 1380 rpm. and simultaneously aerated with one liter of air per minute at a temperature of 28C. for a period of 47 hours. At the end of this period, the pH of the resulting medium is readjusted, if necessary, to pH 6.5 with added sulfuric acid. At this point, 0.75 g. of 3 -n-propyl-8-methyl-9-nitro-2,3 ,4,4a,5 ,6- hexahydro-l H-pyrazino-[ 1,2-a]-quinoline maleate, dissolved in ml. of distilled water, is added to the mixture, and agitation and aeration are both thereafter continued for a period of 23 hours. On completion of this step, the pH is adjusted to pH 8.0 with sodium hydroxide and the mixture is then extracted exhaustively with several portions of methylene chloride. The combined organic extracts are next dried over anhydrous sodium sulfate and filtered, and the filtrate subsequently concentrated in vacuo to near dryness at a temperature below 40C.
The solid residue obtained in this manner is then extracted with methanol (total volume, 50 ml.) at room temperature, and the decanted extracts are subsequently filtered and treated with sodium borohydride, added in small portions over a period of 30 minutes with stirring, to reduce 8-formyl compound present in the mixture to the corresponding S-hydroxymethyl compound. The so-treated methanol solution is then allowed to stand overnight 16 hours) at room temperature and diluted with five volumes of diethyl ether. After washing the resulting ethereal solution with water and drying over anhydrous magnesium sulfate, the ethereal filtrate is subjected to vacuum distillation in a water-bath at 40C. The residue afforded by this procedure is then taken up in isopropanol at 50C. filtered and thereafter cooled overnight in the refrigerator to give a yield of 3-n-propyl-8-hydroxymethyl-9-nitro- 2,3,4,4a,5,6-hexahydro-1H-pyrazino[ l ,2-a]-quinoline as crystalline precipitate.
In like manner, the other 8-hydroxymethyl compounds of the invention are similarly prepared using the appropriate 8-methyl-2,3 ,4,4a,5 ,6-hexahydro- 1 H- pyrazino-[ l,2-a]-quinoline salt as substrate in each case.
EXAMPLE XIX Ten parts by weight of 3-n-propyl-8-hydroxymethyl- 9-nitro-2,3 ,4,4a,5,6-hexahydrol H-pyrazino-[ l ,2-a]- quinoline are added to a dried suspension of 25 parts by weight of active manganese dioxide in 100 parts by volume of benzene and the mixture is stirred under reflux for 6 hours. After cooling, the mixture is filtered and the filtrate is evaporated to dryness to yield 3-npropyl-8-formyl-9-nitro-2,3 ,4,4a,5 ,6-hexahydro- 1 H- pyrazino-[ l ,2-a]-quinoline.
In like manner, the other 8-formyl compounds of this invention are similarly prepared using the appropriate 8-methyl-2,3,4,4a,5,6-hexahydro-lI-I-pyrazino-[ 1,2-a]- quinoline as starting material in each case.
EXAMPLE XX Ten parts by weight of 3-n-propyl-8-methyl-9-nitro- 2,3,4,4a,5,6-hexahydrol H-pyrazino-[ l ,2-a]'quinoline maleate in 50 parts by volume of water are neutralized with lON aqueous sodium hydroxide solution. Extraction of the resulting aqueous solution with several portions of methylene chloride, followed by separation of the organic layer and its subsequent concentration under reduced pressure then affords pure 3-n-propyl-8- methyl-9-nitro-2,3 ,4,4a,5 ,6-hexahydrol H-pyrazino- [l,2-al-quinoline as a free organic base compound.
In like manner, when any of the other substituted hexahydro pyrazinoquinoline salts of this invention, like 8-methyl-9-chloro- 2,3,4,4a,5,6-hexahydrol I-I-pyrazino-[ l,2-a]-quinoline hydrochloride of Example XI, for instance, are each individually subjected to this very same reaction procedure, the corresponding free organic base compound is always the final product thus obtained.
EXAMPLE XXI The following substituted hexahydro pyrazinoquinoline compounds are prepared by employing the procedure described in the previous examples, starting from readily available materials in each instance:
-Continued n R4 r,
COC1H5 CH 7-CN H H COCOOH CH OH 9-F iso-C;,H,- H CO(CH ),COOH CH 7-Cl n-C H; n-C H COC,,H CHO 9-Br H isoC H furoyl CH 7-NO H H thenoyl CH OH 9-CN CH H phthaloyl CH 7-F CH CH picolinoyl CH OH 9-Cl H CH COCH C H CH 7-Br H H EXAMPLE XXII A mixture of 2.0 g. of 3-n-propyl-8-methyl-9-nitro- 2,3,4, 4a,5,6-hexahydro- 1 I-I-pyrazino-[ l,2-a]quinoline and a three molar excess of 30 percent hydrogen peroxide in 15 ml. of acetone is stirred at room temperature 25C) for a period of three days. An additional quantity of 30 percent hydrogen peroxide (a five molar excess) is then added and the stirring thereafter continued for a further seven hours. At this point, the reaction is substantially complete and the excess hydrogen peroxide is decomposed by the addition of platinum oxide to the spent mixture. Upon filtering and removal of the solvent by concentration in vacuo, there is obtained a viscous oil as the liquid residue. Trituration of the latter material with diethyl ether then gives a powdery solid, which is subsequently collected by means of filtration and recrystallized from acetone to afford pure 3-n-propyl-8-methyl-9-nitro-2,3,4,4a,5,6-hexahydrolH-pyrazino-( l,2-a]-quinoline N-oxide as a crytalline solid.
In like manner, the other N-oxide compounds of this invention, where R is other than hydrogen, are each similarly formed by merely employing the appropriate 3-substituted 2,3,4,4a,5 ,6-hexahydrol I-I-pyrazino- [l,2-a]quinoline base as starting material in the above reaction procedure in place of the particular base compound used previously.
EXAMPLE XXIII The non-toxic hydrohalide acid addition salts of each of the substituted hexahydro pyrazinoquinoline bases reported previously in the preceding Examples, viz., the hydrochloride, hydrobromide, and hydroiodide salts, are each individually prepared by first dissolving the respective organic base compound in absolute ether followed by the introduction of the appropriate hydrogen halide gas into the reaction solution until saturation of same is complete with respect to said gas, whereupon the desired salt precipitates from said solution. The crystalline products so obtained are then subsequently re-crystallized from acetone-diethyl ether to yield the pure hydrohalide salt in each case. For instance, when 1.0 g. of 3-n-propyl-8-methyl-9-nitro- 2,3,4,4a,5,6-hexahydro-1H-pyrazino-[1,2-a]-quinoline is dissolved in anhydrous diethyl ether and dry hydrogen chloride gas is subsequently passed into the resulting reaction solution until saturation of same is complete with respect to said gas, there is obtained a crystalline precipitate of 3-n-propyl-8-methyl-9-ntiro- 2,3 ,4,4a,5,6-hexahydro-l H-pyrazino-[ l ,2-a1-quinoline hydrochloride.
EXAMPLE XXIV The nitrate, sulfate, phosphate, acid phosphate, acetate, lactate, citrate acid citrate, tartrate, bitartrate, succinate, maleate, gluconate, saccharate, gluconate, methanesulfonate, ethanesulfonate, benzenesulfonate 21 and p-toluenesulfonate salts of each of the substituted hexahydro pyrazinoquinoline bases previously described in Examples XX-XXI of the instant specification are all each individually prepared by separately dissolving in a suitable amount of ethanol the proper molar amounts of the respective acid and the appropriate organic base compound and the mixing the two solutions together, followed by the addition of diethyl ether to the resulting reaction solution in order to effect precipitation of the desired acid addition salt therefrom. For instance, when equivalent amounts of 8-methyl-9-chloro-2,3 ,4,4a,5 ,6-hexahydro-1H- pyrazino-[l,2-a]-quinoline and concentrated sulfuric acid react in accordance with this procedure, the corresponding final product obtained is 8-methyl-9-chloro- 2,3,4,4a,5,6-hexahydrol H-pyrazino-[ l ,2-a]-quinoline hydrogen sulfate. In like manner, each of the other acid addition salts is similarly prepared.
EXAMPLE XXV 8-Methyl-9-chloro-2,3 ,4 ,4a,5 ,6-hexahydro-1 H- pyrazino-[ 1 ,2-a]-quinoline hydrochloride (2.0 g., equivalent to 1.36 g. of the free organic base) was subjected to fermentative oxidation in the presence of Aspergillus sclerotiorum Huber, employing the fermentation procedure hereinafter described in Example XXXI, with 0.5 g. of said starting material being added to each of the four fermenters as described in said Example. Upon evaporation of the dried methylene chloride extract, there were ultimately obtained 1.738 g. of a pale yellow powder melting at l55-l60C.
The latter was then dissolved in 85 ml. of isopropanol at 60C. and the resulting solution thereafter refrigerated for a period of three hours. The precipitate which formed at this point was subsequently recovered by means of suction filtration and dried in vacuo at room temperature (=25C.) to give a 0.4 g. yield of 8-' hydroxymethyl-9-chloro-2,3 ,4,4a,5 ,6-hexahydrol H- pyrazino-[ l ,2-a]-quinoline as an off-white powder, m.p. l68169C. A further 0.15 g. of material (m.p. 168-169C.) was obtained from the mother liquor on evaporation of said filtrate at room temperature to give a total conversion yield of 44 percent. Anal.
Calcd. for C, H, ClN O: C, 61.77; H, 6.78; N, 11.09.
Found: C, 61.99; H, 6.55; N, 10.59.
EXAMPLE XXVI 2-(N,N-Diethylaminomethyl)-6-Methyl-7-Nitro- 1,2,3 ,4-Tetrahydroquinoline (l) 200 Grams of 6-methylquinoline-2-carboxylic acid is suspended in 5 liters of dry toluene and treated with phosphorus pentachloride (1 mole per mole of acid) and refluxed for 2 hours. After decolorizing with charcoal and filtering, the solution of the acid chloride so formed is cooled to room temperature in the absence of moisture and then added to a solution of diethylamine (2 moles per mole of original acid) in dry toluene (3 volumes per volume of diethylamine). The bright red product is stirred for y hour and then washed with water and dried over anhydrous sodium sulfate. After distilling off the toluene in vacuo, the solid residue is crystallized from ethanol to yield 2- (N,N-diethylcarbamoyl)-6-methylquinolinc (m.p. ll7l 19C., overall yield 65-75 percent).
(2) A solution of 35 g. of the product of (l) in 350 ml. of dry dioxane is added slowly to a stirred suspension of lithium aluminum hydride [1.5 moles per mole of product of (1)] in dry dioxan (25 ml. per g. of LiAlH The mixture is stirred at reflux temperature for 5 hours and then cooled in an ice bath. Water is added cautiously to destroy excess LiAll-L. After filtration, the solution is distilled in vacuo to dryness. The residual oil (30 g.) is dissolved in 450 ml. of methanol and hydrogenated in an autoclave at C. and 750 p.s.i. in the presence of Raney nickel for 4 hours. The product is cooled to room temperature, filtered and distilled in vacuo to yield 2-(N,N-diethylaminoethyl)- 6-methyl-l ,2,3,4-tetrahydroquinoline [b.p. l20l30C. at 0.2 mm. Hg: overall yield of stage (2) 35-50%].
(3) 20 Grams of the product of (2) is added dropwise to 500 ml. of concentrated sulfuric acid cooled in ice and stirred during the addition. The mixture is then warmed gently to 20C. to form a clear solution, cooled again in ice to below 5C. and treated with a 10 percent solution of fuming nitric acid [S.g. 1.5, 1 mole per mole of product of (2)] in concd., sulfuric acid, added dropwise with stirring to keep the temperature below 5C. After stirring on the ice bath for a further 3 hours, the solution is poured onto ice and neutralized with sodium bicarbonate. The product separted as a red oil, to gether with sodium sulfate, and is collected by filtering and washing with ether. The filtrate is extracted with ether and the combined ether extracts and washings are dried to yield 2-(N,N-diethylaminomethyl)-6-methyl- 7-nitro l ,2,3,4-tetrahydroquinoline as a red oil, which is crystallized from 60/80C. petrol-ether at C. in a bath of chloroform and solid carbon dioxide. After drying, the product melted at 52-54C. (yield 50 per cent) and gave the following analysis:
Anal.
Calcd. for C H N O C, 64.9; H, 8.35; N, 15.15. Found: C, 64.86; H, 8.33; N, 14.95.
EXAMPLE XXVII 2-lsopropylaminomethyl-6-methyl-7-nitro-l ,2,3,4- tetrahydroquinoline (l) 2,6-Dimethylquinoline (314 g., 2.0moles) is dissolved in 1 liter carbon tetrachloride and sodium carbonate (200 g.) added, stirred and warmed to 60C. Heat is removed and chlorine passed into the solution at 300-400 ml./min., the temperature being controlled at about 60C. After 5.5 hours, reaction is complete and the product starts crystallizing out of solution. The reaction products are then cooled and poured into 1 liter of 2N hydrochloric acid. The organic layer is separated and extracted 3 times with 1 liter of 2N hydrochloric acid. The combined acid layers are washed with methylene dichloride (500 ml.) and then basified with sodium carbonate, when 2-chloromethyl-6- methylquinoline separated as a pale buff solid. Filtramethylene dichloride. The combined organic layers are dried and evaporated to yield 2-isopropylamino-5- methylquinoline as a dark oil (249 g.).
(3) 235 Grams of the product of (2) are dissolved in 1.4 liter methylated spirit and hydrogenated in the presence of Raney nickel at 750 p.s.i. and 75C. (complete after 2 /2 hours). After filtration and cooling to C., 120 g. of concd. H 80 are added dropwise over V2 hour, further solvent being added as necessary. The precipitate is then filtered, washed with acetone and ether, and dried to yield 300 g. of 2- isopropylaminomethyl-6-methyl-1 ,2,3,4- tetrahydroquinoline hydrogen sulfate as a white amorphous solid (m.p. 145l58C.).
(4) 253 Grams of the product of (3) is nitrated as described in Example XXVI, (3), except that neutralization is carried out with ION sodium hydroxide. The orange oily product is extracted into methylene dichloride, evaporated, redissolved in ethyl acetate, dried and evaporated, and then converted to the maleate salt by conventional means. Crystallization from methylated spirit yielded 144 g. of 2-isopropylaminomethyl-6- methyl-7-nitro-1 ,2,3,4-tetrahydroquinoline hydrogen maleate as dark brown needles (m.p. 183184C.). Anal.
Calcd. for C H N O C, 57.01; H, 6.60; N, 11.08.
Found: C, 57.06; H, 6.50; N, 11.14.
EXAMPLE XXVlll 2-(N-t-Butylaminomethyl)-6-methyl-7-nitro-1,2,3,4- tetrahydroquinoline (1) A mixture of 2-formyl-6-methylquinoline (10.25 g., 0.06 mole) and tertiary-butylamine (17.52 g.; 0.24 m) in absolute alcohol (200 c.c.) is hydrogenated over percent palladium on barium sulfate catalyst (10 g.) at 50 p.s.i. for one hour. The catalyst is removed by filtration and evaporation of the solvent yielded a brown mobile 011 which is distilled to give 2-(N-tertbutylaminomethyl)-6-methylquinoline as a goldenyellow mobile oil of hp l42C./0.7 mm. Hg (yield 1 1.7 g.). (2) Ten grams of the product of l in ethanol (175 c.c.) is hydrogenated over Raney nickel (2 m1.) at 75C. and 750 p.s.i. for four hours. The catalyst is removed by filtration and the alcohol evaporated in vacuo to yield an oil which is fractionally distilled to give 2-(N-tertiary-butylaminoethyl)6-methyl-1,2,3,4- tetrahydroquinoline of b.p. l130C./0.6 mm. Hg. (yield 8.6 g.).
3) 5.34 Grams of the product of 2) is nitrated as in Example XXVI (3). The dark red oil product is extracted into chloroform, dried and evaporated in vacuo and then chromatographed on a column of neutral alumina. Elution with 50 percent mixture of benzene and chloroform removes an orange band and evaporation of the solvent gives 2-(N-tert.-butylaminomethyl)-6- methyl-7-nitro-l,2,3,4-tetrahydroquinoline as a bright red solid of m.p. 63-68C.
Anal.
Calcd. for C, H N O C, 65.00; H, 8.30; N, 15.16.
Found: C,.64.60; H, 8.10; N, 15.35.
EXAMPLE XXlX l) A solution of 10 g. of 2-bromomethyl-7-chloro-6- methylquinoline in a mixture of 100 ml. of ethanol and 200 ml. chloroform at room temperature is added over a period of 5 minutes to a solution of 8.1 g. of diethylamine in 100 ml. ethanol with stirring. The solution is then allowed to stand at room temperature for 15 hours and the solvents are distilled off under vacuum. The oily residue is triturated with about 100 ml. water, the product extracted into chloroform and traces of excess diethylamine removed by washing the chloroform solution with water three times. The chloroform solution is then dried over magnesium sulfate and distilled in vacuo to dryness. The residual oil is dissolved in about 200 ml. of dry ether and dry hydrogen chloride gas is bubbled through the solution to precipitate 7-chloro-2- dimethylaminomethyl-6-methylquinoline hydrochloride. The salt crystallized on standing and is collected and recrystallized from ethanol, with a little ether added to ensure a good recovery of product. This gave 6.6 g. of white crystalline material of m.p. 196202C.
(2) The product of 1) is hydrogenated in the presence of Raney nickel as described in Example XXVlll. The green residue after evaporation of the ethanol is triturated with, an ethyl acetate/ligroin mixture until a solid crystalline product is obtained. This product recrystallizes from isopropanol/ether to give 7-chloro-2- diethylaminomethyl-6-methyl-l ,2,3,4- tetrahydroquinoline hydrochloride a white crystalline product of m.p. 172l73C.
Anal.
Calcd. for C, l-l Cl N C, 59.4; H, 8.0; N, 9.25. Found: C, 58.97; H, 7.99; N, 9.00.
EXAMPLE XXX 2-Diethylaminomethyl-4,6-dimethyl-7-nitro- 1 ,2,3 ,4- tetrahydroquinoline (1) 2,4,6-Trimethylquinoline (40 g., 0.234 mole) is chlorinated in a manner analogous to that described in Example XXVIl (1) to give 2-chloromethyl-4,6- dimethylquinoline as a buff colored powder. Recrystallization from 40/60C. petroleum ether gives 23 g. of very pale, yellow needles, mp. 606lC.
(2) 15 Grams of the product of 1) suspended in absolute ethanol (100 ml.) is treated with diethylamine (20 ml., 14.2 g.) and complete dissolution brought about by warming. The mixture is then left to stand overnight and the ethanol distilled off under reduced pressure. The semi-solid residue is treated with excess 2N sodium hydroxide solution and extracted with two- 200 ml. portions of ether. The combined extracts are dried over magnesium sulfate, the ether evaporated off and the residual oil fractionated under reduced pressure. 2-Diethylaminomethyl-4,6-dimethylquinoline distilled at 1 19C./0. l 8 mm. Hg. as a very pale yellow oil.
(3) l5 Grams of the product of (2) is hydryogenated as described in Example XXVllI (2), fractional distillation yielding 3.7 g. of 2,4,6-trimethyl-l,2,3,4- tetrahydroquinoline (b.p. -110C. at 1.0-1.5 mm. Hg.) and 2.0 g. of Z-diethylaminomethy1-4,6-dimethyl- 1,2,3,4-tetrahydroquinoline as a pale yellow oil (b.p. 112C. at 0.20 mm. Hg.).
(4) 1.5 Grams of the latter product of (3) is nitrated and converted to the maleate salt as in Example XXVll (4) and recrystallized from ethyl acetate, containing a trace of methanol, to yield 0.65 g. of 2- 25 diethylaminomethyl-4,6-dimethyl-7-nitro- 1 ,2,3,4- tetrahydroquinoline hydrogen maleate as red needles, mp. 131132C.
Anal.
Calcd. for C H N O C, 58.9; H, 7.17; N, 10.31. Found: C, 58.80; H, 7.08; N, 10.17.
EXAMPLE XXXl 6-Hydroxymethyl-2-lsopropylaminoethyl-7-Nitrol ,2,3 ,4-Tetrahydroquinoline (1) Four fermenters are set up, each one of which contained 2.0 liters of the following medium, sterilized for thirty-five minutes at 15 p.s.i. via an autoclave:
Grams Soybean meal Glucose 20 Sodium chloride 5 Potassium hydrogen phosphate 5 Yeast Extract 5 Tap water, in sufficient amount for a 1000 ml. solution, adjusted to pH 6.5 with concentrated sulfuric acid.
The fermenters are inoculated with 7.5 percent by volume of a twenty-four hour old culture of Aspergillus sclerotiorum Huber grown at 28C. in 50 ml. aliquots of the above described soybean-glucose medium contained in 200 ml. Erlenmeyer flasks, placed on a shaker rotating at approximately 230 r.p.m. The inoculated fermenters are agitated at 1380 r.p.m. and each aerated withl liter of air per minute and at a temperature of 28C. for forty-seven hours. A silicone anti-foam is added when required. At the end of the forty-seven hour period, the pH of the fermentation broth rose to 6.8-6.9. Sulfuric acid is added with sterile precautions to restore the pH to 6.5.
(2) 0.75 Gram of the product of Example XXVll, as hydrogen maleate, dissolved in 75 ml. of sterile water is added to each of the four ferrnenters and agitation and aeration are continued for a further twenty-three hours. The whole fermentation broths from each fermenter are pooled, the pH adjusted to 8.0 with sodium hydroxide and the 8.2 liters of fermentation broth thus obtained are extracted by agitating vigorously with 16.4 liters of methylene chloride for ten minutes. The solvent extract is dried over anhydrous sodium sulfate and then evaporated to dryness at a temperature below 40C. (dry weight 5.567 g.).
(3) The dark brown residue from (2) is extracted four times with methanol at room temperature, decanting the solution from the insoluble material. The combined methanol extracts, total volume about 200 ml., are then filtered and treated with 3 g. of sodium borohydride, added in portions over a period of 30 minutes with stirring, to reduce any 6-formy1 compound present to the 6-hydroxymethyl compound. The methanol solution is allowed to stand overnight at room temperature and is then diluted with 1 liter of ether. The solution is washed 4 times with 500 ml. of water and the resulting pale yellow'ethereal solution is dried over magnesium sulfate. The ether is removed by vacuum distillation from a water bath at 40C. The residue is dissolved in about 75 ml. of isopropanol at 50C., filtered to remove any insoluble particles and cooled overnight in the refrigerator. The product is collected and dried in vacuo to yield 0.5 g. of 6-hydroxymethy1-2- isopropylaminomethyl-7-nitro-1 ,2,3 ,4- tetrahydroquinoline as pale yellow crystals of m.p.
147149C. A further 0.5 g. of crude material is obtained from the mother liquors of the recrystallization. Total yield is therefore 1.0 g. (0.0036 mole) from 3.0 g. (0.0079 mole) of starting material, i.e., 45 percent of theoretical. Anal.
Calcd. for C ,H N O C, 60.15; H, 7.58; N, 15.04.
Found: C, 59.93; H, 7.84; N, 14.82.
What is claimed is:
1. A method for the treatment of schistosomiasis, which coprises administering to a host infected with schistosomes an effective anti-schistosomicidal amount of a compound selected from the group consisting of substituted 2,3,4,4a,5,6-hexahydro-1H-pyrazino-[1,2- al-quinoline bases of the formula:
and the pharmaceutically acceptable acid addition salts thereof, wherein R is hydrogen, allyl, B-hydroxyethyl or alkyl having from one to four carbon atoms, R is methyl or hydroxymethyl, R is nitro, fluorine, chlorine or bromine located at either the 7- or 9-position of the molecule, R, is hydrogen and R is hydrogen or methyl.
compound administered is 7-chloro-8-methyl- 2,3,4,4a,5,6-hexahydro-lH-pyrazino-[1,2-a]- quinoline.
5. The method as claimed in claim 1 wherein the compound administered is 8-methy1-9-chloro- 2,3 ,4,4a,5,6-hexahydro-l H-pyrazino-[ 1 ,2-a]- quinoline.
6. The method as claimed in claim 1 wherein the compound administered is 3,8-dimethyl-9-chloro- 2,3 ,4,4a,5,6-hexahydro- 1 H-pyrazino-[ 1 ,2-a]- quinoline.
7. The method as claimed in claim 1 wherein the compound administered is 3-n-propyl-8-methyl-9- chloro-2,3 ,4,4a,5,6-hexahydrol H-pyrazino-[ l,2-a]- quinoline.
8. The method as claimed in claim 1 wherein the compound administered is 8,l0-dimethyl-9-chloro 2,3,4,4a,5,6-hexahydro-l H-pyrazino-[ l 221]- quinoline.
9. The method as claimed in claim 1 wherein the compound administered is 3-allyl-8-methyl-9-nitro- 2,3 ,4,4a,5,6-hexahydrol H-pyrazino-[ l ,2-a]- quinoline.
10. The method as claimed in claim 1 wherein the compound administered is 3-(B-hydroxyethy1)-8- methyl-9-nitro-2,3,4,4a,5,6-hexahydro-1H-pyrazino- [l,2-a]-quinoline.
11. The method as claimed in claim 1 wherein the compound administered is 8-hydroxymethyl-9-chloro- 2,3,4,4a,5,6-hexahydro-l H-pyrazino-[ l ,2-a]- quinoline.

Claims (10)

  1. 2. The method as claimed in claim 1 wherein the compound administered is 3-n-propyl-8-methyl-9-nitro-2,3,4,4a,5,6-hexahydro-1H-pyrazino-(1,2-a) -quinoline.
  2. 3. The method as claimed in claim 1 wherein the compound administered is 3-isopropyl-8-methyl-9-nitro-2,3,4,4a,5,6-hexahydro-1H-pyrazino-(1,2-a) -quinoline.
  3. 4. The method as claimed in claim 1 wherein the compound administered is 7-chloro-8-methyl-2,3,4,4a,5,6-hexahydro-1H-pyrazino-(1,2-a)-quinoline.
  4. 5. The method as claimed in claim 1 wherein the compound administered is 8-methyl-9-chloro-2,3,4,4a,5,6-hexahydro-1H-pyrazino-(1,2-a)-quinoline.
  5. 6. The method as claimed in claim 1 wherein the compound administered is 3,8-dimethyl-9-chloro-2,3,4,4a,5,6-hexahydro-1H-pyrazino-(1,2-a)-quinoline.
  6. 7. The method as claimed in claim 1 wherein the compound administered is 3-n-propyl-8-methyl-9-chloro-2,3,4,4a,5,6-hexahydro-1H-pyrazino-(1,2-a) -quinoline.
  7. 8. The method as claimed in claim 1 wherein the compound administered is 8,10-dimethyl-9-chloro-2,3,4,4a,5,6-hexahydro-1H-pyrazino-(1,2-a)-quinoline.
  8. 9. The method as claimed in claim 1 wherein the compound administered is 3-allyl-8-methyl-9-nitro-2,3,4,4a,5,6-hexahydro-1H-pyrazino-(1,2-a) -quinoline.
  9. 10. The method as claimed in claim 1 wherein the compound administered is 3-( Beta -hydroxyethyl)-8-methyl-9-nitro-2,3,4, 4a,5,6-hexahydro-1H-pyrazino-(1,2-a)-quinoline.
  10. 11. The method as claimed in claim 1 wherein the compound administered is 8-hydroxymethyl-9-chloro-2,3,4,4a,5,6-hexahydro-1H-pyrazino-(1,2-a) -quinoline.
US00379009A 1969-01-07 1973-07-13 Hexahydro pyrazinoquinolines as antischistosomal agents Expired - Lifetime US3829573A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US00379009A US3829573A (en) 1969-01-07 1973-07-13 Hexahydro pyrazinoquinolines as antischistosomal agents

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78961069A 1969-01-07 1969-01-07
US00379009A US3829573A (en) 1969-01-07 1973-07-13 Hexahydro pyrazinoquinolines as antischistosomal agents

Publications (1)

Publication Number Publication Date
US3829573A true US3829573A (en) 1974-08-13

Family

ID=27008435

Family Applications (1)

Application Number Title Priority Date Filing Date
US00379009A Expired - Lifetime US3829573A (en) 1969-01-07 1973-07-13 Hexahydro pyrazinoquinolines as antischistosomal agents

Country Status (1)

Country Link
US (1) US3829573A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997029095A1 (en) * 1996-02-06 1997-08-14 Hoechst Schering Agrevo Gmbh 2,4-diamino-1,3,5-triazines, processes for their preparation and their use as herbicides and plant-growth regulators

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997029095A1 (en) * 1996-02-06 1997-08-14 Hoechst Schering Agrevo Gmbh 2,4-diamino-1,3,5-triazines, processes for their preparation and their use as herbicides and plant-growth regulators
US6071860A (en) * 1996-02-06 2000-06-06 Hoechst Schering Agrevo Gmbh 2,4-Diamino-1, 3,5-triazines, their preparation, and their use as herbicides and plant growth regulators

Similar Documents

Publication Publication Date Title
US3960861A (en) 2 (OR 4) Amino 4 (or 2) N-hetero quinazolines
US3950343A (en) Pyrroloisoquinoline derivatives
JPH054983A (en) Isoquinolinone derivative, its production and 5-ht3 receptor antagonist containing the derivative as active component
EP0319429B1 (en) 9-Acylamino-tetrahydroacridine derivatives and memory enhancing agent containing said derivative as active ingredient
US3925391A (en) 2-Aminoalkyl tetrahydroquinolines
US3529062A (en) Indole derivatives as antitussive agents
GB1583352A (en) 1,2-dihydronaphthalene derivatives and production thereof
US3267107A (en) 3-(4'-5'-methylenedioxy-phenyl)-7, 8-dimethoxy-1, 2, 3, 4,-tetrahydroisoquinolines
JPS6123790B2 (en)
US3752823A (en) N alkyl tetrahydrocarbazoles
NZ218987A (en) Benzazecine 3,8 dione derivatives and benzoquinoline intermediates and pharmaceutical compositions
US3668208A (en) Hexahydro imidazoquinolines
US4218448A (en) Antihypertensive polyfluorohydroxyisopropyl bicyclic and tricyclic carbostyrils
US3829573A (en) Hexahydro pyrazinoquinolines as antischistosomal agents
US3978064A (en) 3-Aminomethylene-6,7-dimethoxy-2-methyl-4-oxo-1,2,3,4-tetrahydro-1-quinoline carboxylic acid esters and intermediates leading thereto
US4044136A (en) Aminoquinazoline therapeutic agents
US3899490A (en) Hexahydro pyrazinoquinolines
EP0127412B1 (en) Imidazolidinedione derivatives
JPH10505333A (en) Imidazopyridine-azolidinone
US3629265A (en) 7-halo-4-isoquinolones
EP0270692A1 (en) Antiarrhythmic agent
US4022778A (en) 10-Aryl-1,2,3,4-tetrahydropyrazino(1,2-α)indole and derivatives thereof
US4260612A (en) Antiallergic nitrogen bridge-head compounds
US4469694A (en) 2-(1-Piperazinyl)-2,4,6-cycloheptatrien-1-one derivatives
EP0308059B1 (en) 1,2,3,4-tetrahydroisoquinoline antiarrhythmic agents